temozolomide has been researched along with Skin Neoplasms in 149 studies
Skin Neoplasms: Tumors or cancer of the SKIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this phase I study was to determine the maximum tolerated dose of the combination of TPI 287 and temozolomide in metastatic melanoma." | 9.22 | A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. ( Amaria, RN; Bassett, RL; Bedikian, AY; Cain, S; Davies, MA; Hwu, P; Hwu, WJ; Lecagoonporn, S; McQuade, JL; Patel, SP; Posada, LP, 2016) |
| "We conducted a single-arm phase II multi-institution cooperative group study to assess the antitumor activity and safety profile of the combination of TMZ and the rapamycin derivative everolimus in patients with metastatic unresectable malignant melanoma." | 9.19 | Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. ( Allred, JB; Creagan, ET; Dronca, RS; Kaur, JS; Lieser, EA; Maples, WJ; Marchello, BT; Markovic, SN; Moore, TD; Nevala, WK; Perez, DG; Pockaj, BA; Thompson, M, 2014) |
| "This study showed that temozolomide (150-200 mg/m(2)/day) can safely be given with a PARP inhibitory dose of rucaparib, increasing progression-free survival over historical controls in metastatic melanoma patients." | 9.17 | A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. ( Abbattista, A; Calvert, H; Curtin, N; Dewji, R; Gallo, J; Lorigan, P; Middleton, MR; Mulligan, E; Plummer, R; Scott, L; Steven, N; Wang, D; Wilson, RH, 2013) |
| "The combination of oblimersen, temozolomide, and nab-paclitaxel was well tolerated and demonstrated encouraging activity in patients with advanced melanoma." | 9.17 | Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. ( Chang, J; Cheng, X; Escano, C; Gandhi, A; Kannan, R; Liebes, L; Madden, K; Mendoza, S; Muren, C; Ott, PA; Pavlick, AC; Shao, Y, 2013) |
| "Temozolomide (TMZ) is widely used for chemotherapy of metastatic melanoma." | 9.17 | Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. ( Beumer, JH; Buch, SC; Christner, S; Egorin, MJ; Kirkwood, JM; Lin, Y; Moschos, S; Tarhini, AA; Tawbi, HA, 2013) |
| "Previously untreated metastatic melanoma patients with Eastern Cooperative Oncology Group performance status of two or more were treated with temozolomide 150 mg/m(2) days 1-7 orally and bevacizumab 10 mg/kg body weight i." | 9.16 | First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). ( Cathomas, R; Dummer, R; Gillessen, S; Goldinger, SM; Mamot, C; Michielin, O; Mjhic-Probst, D; Moch, H; Ochsenbein, A; Schläppi, M; Schönewolf, N; Schraml, PH; Seifert, B; Simcock, M; von Moos, R, 2012) |
| "To compare the efficacy of an extended schedule escalated dose of temozolomide versus standard dose dacarbazine in a large population of patients with stage IV melanoma." | 9.15 | Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). ( Agarwala, SS; Becker, J; Conry, R; Davidson, N; Dummer, R; Eggermont, AM; Engelen, K; Hwu, WJ; Keilholz, U; Kruit, WH; Mortier, L; Patel, PM; Punt, CJ; Robert, C; Schadendorf, D; Spatz, A; Suciu, S; Thompson, JA; Trefzer, U, 2011) |
| "This study compared the central nervous system (CNS) metastasis incidence between a temozolomide- and a dacarbazine-based regimen in untreated stage IV melanoma patients." | 9.15 | Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. ( Brugnara, S; Chiarion-Sileni, V; Colucci, G; De Salvo, GL; Del Bianco, P; Guida, M; Pigozzo, J; Ridolfi, L; Ridolfi, R; Romanini, A, 2011) |
| "In a search for more effective combination chemotherapy for the treatment of metastatic melanoma, we conducted a phase I trial of a novel combination of docetaxel, temozolomide, and cisplatin." | 9.14 | Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. ( Bedikian, AY; Camacho, LH; Frost, AM; Hernandez, IM; Hwu, P; Hwu, WJ; Jack, MA; Kim, KB; Ng, C; Papadopoulos, NE, 2009) |
| "Patients must have had stage IV cutaneous melanoma, no active brain metastases, Zubrod PS 0-1, up to 1 prior systemic therapy excluding thalidomide, temozolomide, or dacarbazine, adequate organ function, and given informed consent." | 9.14 | Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. ( Clark, JI; Da Silva, DM; Flaherty, LE; Hutchins, LF; Kast, WM; Liu, PY; Moon, J; Sondak, VK; Sosman, JA; Thompson, JA, 2010) |
| "Preclinical studies show that bortezomib, a proteasome inhibitor, blocks NF-kappaB activation and, combined with temozolomide, enhances activity against human melanoma xenografts and modulates other critical tumor targets." | 9.14 | A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. ( Amiri, KI; Ayers, GD; Horton, LW; Kelley, MC; Koehler, E; Puzanov, I; Richmond, A; Sosman, JA; Su, Y; Yu, Y, 2010) |
| "Temozolomide (TMZ) is a second-generation alkylating agent that has recently shown some efficacy in stage IV melanoma." | 9.14 | Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial. ( Bedane, C; Guillet, G; Guillot, B; Mourey, L; Sassolas, B; Tourani, JM; Wierzbicka-Hainaut, E, 2010) |
| "We conducted a single institution phase II trial to evaluate the tolerability and effectiveness of therapy with arsenic trioxide (ATO) and ascorbic acid (AA) with temozolomide (TMZ) in patients with advanced melanoma." | 9.13 | Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. ( Bael, TE; Gollob, JA; Peterson, BL, 2008) |
| "Our objective was to evaluate the toxicity and antitumor efficacy of concurrent biochemotherapy in metastatic melanoma patients and the effectiveness of adding temozolomide to protect the brain from metastases." | 9.12 | A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study. ( Asna, N; Inbar, MJ; Metser, U; Ron, IG; Ryvo, L; Safra, T; Sapir, EE; Sarid, D; Schneebaum, S, 2006) |
| "Temozolomide and interferon-alpha-2b (IFN-alpha-2b) are both active in melanoma." | 9.12 | Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. ( Aird, S; Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Panageas, KS; Williams, LJ; Wolchok, JD, 2006) |
| "To assess the efficacy and tolerability of extended dose temozolomide and continuous thalidomide in patients with advanced metastatic cutaneous melanoma." | 9.12 | A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. ( Arce-Lara, C; Kloecker, GH; Laber, DA; McMasters, KM; Miller, DM; Okeke, RI; Schonard, CL; Taft, BS, 2006) |
| "Temozolomide is a novel oral alkylating agent, active against metastatic melanoma." | 9.12 | Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma. ( Crespo, C; del Muro, XG; Filipovich, E; García, M; Germà-Lluch, JR; López, JJ; Pérez, X; Rifà, J; Tres, A; Valladares, M, 2006) |
| "The combination of TMZ and celecoxib is safe and potentially effective in the treatment of metastatic melanoma." | 9.12 | Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. ( Fountzilas, G; Frangia, K; Gogas, H; Mantzourani, M; Markopoulos, C; Middleton, M; Panagiotou, P; Papadopoulos, O; Pectasides, D; Polyzos, A; Stavrinidis, I; Tsoutsos, D; Vaiopoulos, G, 2006) |
| "Preliminary studies suggesting that extended-dose temozolomide with thalidomide is safe and active in patients with metastatic melanoma have led to frequent use of this oral regimen." | 9.12 | Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). ( Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D, 2006) |
| "Temozolomide has shown some efficacy in metastatic melanoma and recently received extended approval to treat brain tumours." | 9.12 | Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. ( Egberts, F; Garbe, C; Hauschild, A; Kreissig, M; Linse, R; Mohr, P; Schadendorf, D; Thoelke, A; Tilgen, W; Trefzer, U; Ugurel, S; Vogt, T, 2006) |
| "To evaluate tumor response, pharmacodynamic effects, and safety of a combination of lomeguatrib (LM), an O6-methylguanine DNA-methyltransferase (MGMT) inactivator, and temozolomide (TMZ), TMZ alone, and LM/TMZ after disease progression on TMZ alone in patients with advanced melanoma." | 9.12 | Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. ( Baka, S; Beith, J; Davis, ID; Harris, PA; Haydon, A; Hersey, P; Kefford, RF; Margison, GP; McArthur, GA; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Seebaran, A; Thompson, D; Watson, AJ, 2007) |
| "A multicentre, centrally randomized, open-labelled study with temozolomide and interferon (IFN)-alpha 2b was carried out to study the therapeutic effect in patients with metastatic melanoma stage IV." | 9.11 | Temozolomide and interferon alpha 2b in metastatic melanoma stage IV. ( Fialla, R; Forstinger, Ch; Fritsch, P; Hofmann-Wellenhof, R; Kehrer, H; Kerl, H; Kindermann-Glebowski, E; Klein, G; Koller, J; Konrad, K; Kos, C; Lang, A; Mischer, P; Pachinger, W; Pehamberger, H; Raml, J; Ratzinger, G; Richtig, E; Seeber, A; Smolle, J; Steiner, A; Ulmer, H; Wolff, K; Zelger, B, 2004) |
| "Temozolomide plus thalidomide was an active oral regimen for patients with brain metastases from malignant melanoma." | 9.11 | Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. ( Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Lis, E; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Williams, LJ; Wolchok, JD, 2005) |
| "The present study was designed to assess the efficacy and safety of combination therapy with temozolomide plus cisplatin in patients with metastatic melanoma." | 9.11 | Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial. ( Argon, A; Camlica, H; Tas, F; Topuz, E, 2005) |
| "Temozolomide is an imidazotetrazine with a mechanism of action similar to dacarbazine and equivalent activity in melanoma." | 9.10 | Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. ( Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N, 2003) |
| "Temozolomide is an oral alkylating agent that readily crosses the blood-brain barrier and has activity in patients with advanced melanoma." | 9.10 | A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma. ( Boxall, J; Marples, M; Meyer, T; Napier, MP; Rustin, GJ; Strauss, SJ, 2003) |
| "Temozolomide is a novel oral alkylating agent that is effective against melanoma." | 9.10 | Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. ( Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D, 2002) |
| "To evaluate the antitumor effects and toxicities of whole brain irradiation (WBI) with temozolomide (TMZ) administered by prolonged oral dosing in patients with melanoma metastatic to the brain." | 9.10 | Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. ( Atkins, B; Clark, I; Dutcher, P; Ernstoff, S; Flaherty, L; Gollob, J; II Smith, W; Johnson, D; Longmate, J; Margolin, K; Sosman, J; Thompson, A; Weber, J; Weiss, G, 2002) |
| "To determine the potential economic implications resulting from oral temozolomide (TEM) compared with intravenous (IV) dacarbazine (DTIC) for metastatic melanoma." | 9.09 | Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma. ( Agarwala, S; Hillner, BE; Middleton, MR, 2000) |
| " The authors hereby, evaluated the use of temozolomide (TMZ) for treating metastatic melanoma compared to dacarbazine (DTIC), the effectiveness of TMZ for treating brain metastases, as well as TMZ resistance and how the efficacy of TMZ in malignant melanoma can be increased." | 8.91 | Temozolomide for Treating Malignant Melanoma. ( Hou, XY; Jiang, G; Li, RH; Liu, WL; Liu, YQ; Tang, JQ; Yang, CS, 2015) |
| " Two chemotherapeutic regimens are commonly used for the palliative treatment of malignant melanoma: intravenous administration of single-agent dacarbazine or oral administration of temozolomide." | 8.89 | Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients. ( Abdollahi, M; Nikfar, S; Teimouri, F, 2013) |
| "To assess the efficacy of single-agent temozolomide, a standard agent is used for metastatic melanoma in late adjuvant chemotherapy for cutaneous melanoma." | 8.02 | Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma. ( Erturk, K; Tas, F, 2021) |
| "To investigate the predictive and prognostic value of O(6) -methylguanine DNA methyltransferase (MGMT) inactivation by analyses of promoter methylation in pretreatment tumor biopsies from patients with cutaneous melanoma treated with dacarbazine (DTIC) or temozolomide (TMZ) were performed." | 7.81 | MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma. ( Egyházi Brage, S; Frostvik Stolt, M; Hansson, J; Hertzman Johansson, C; Jewell, R; Johansson, H; Lindén, D; Lindholm, C; Newton-Bishop, J; Snowden, H; Stierner, U; Tuominen, R; van den Oord, JJ; Walker, C; Wolter, P, 2015) |
| "This study was performed to evaluate the addition of temozolomide (TMZ) to whole brain radiotherapy (WBRT) for brain metastases from melanoma." | 7.76 | Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy? ( Bearden, JD; Behl, D; Brown, PD; Deming, RL; Markovic, SN; Rowland, KM; Sande, JR; Schild, SE, 2010) |
| "All patients with metastatic melanoma treated with either dacarbazine (DTIC) or temozolomide (TMZ) at the British Columbia Cancer Agency (BCCA) from January 1, 1988 to February 1, 2006 were identified through the BCCA pharmacy electronic database, which was then linked to the surveillance and outcomes unit to identify patients with LTS, defined as survival > or =18 months following chemotherapy." | 7.76 | Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide. ( Kim, C; Klasa, R; Kovacic, L; Lee, CW; Savage, KJ; Shah, A, 2010) |
| " A 67-year-old renal transplant recipient developed a nodular malignant melanoma after 30 years of immunosuppression with azathioprine and prednisolone." | 7.75 | Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine. ( Guenova, E; Hoetzenecker, W; Lichte, V; Moehrle, M; Roecken, M; Schaller, M; Woelbing, F, 2009) |
| "Five different human melanoma xenografts were used in a xenograft model of extremity melanoma to evaluate the variability of tumor response to regionally administered melphalan or temozolomide and to determine if various components of pertinent drug resistance pathways for melphalan [glutathione S-transferase (GST)/glutathione] and temozolomide [O(6)-alkylguanine DNA alkyltranferase (AGT)/mismatch repair (MMR)] could be predictive of tumor response." | 7.74 | Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. ( Ali-Osman, F; Augustine, CK; Friedman, HS; Pruitt, SK; Selim, MA; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA, 2007) |
| "Temozolomide is an oral alkylating agent used in the treatment of metastatic melanoma." | 7.74 | Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma. ( Neff, WJ; Nystrom, KK; Pick, AM, 2008) |
| "The aim of this study was to determine the efficacy and tolerability of a biochemotherapy regimen, including low-dose subcutaneous interleukin-2 and temozolomide, in patients with metastatic melanoma." | 7.73 | Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma. ( Carrera, C; Castel, T; Conill, C; Gascón, P; González Cao, M; Herrero, J; Malvehy, J; Martí, R; Martín, M; Mellado, B; Puig, S; Sánchez, M, 2006) |
| "This study investigated whether the therapeutic index of regional melanoma therapy using parenteral temozolomide could be improved by chemomodulation with O6-benzylguanine (O6BG), an inhibitor of the DNA repair enzyme O6-alkylguanine-DNA alkyltransferase (AGT)." | 7.73 | Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. ( Abdel-Wahab, OI; Abdel-Wahab, Z; Augustine, C; Cheng, TY; Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T; Yoshimoto, Y, 2006) |
| "Ten patients with malignant melanoma and phototoxic reactions under dacarbazine or 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC) chemotherapy were investigated." | 7.72 | Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma. ( Geilen, CC; Georgieva, J; Orfanos, CE; Treudler, R, 2004) |
| "The present observation suggests that temozolomide may be an active and well tolerated treatment for malignant melanoma brain metastases." | 7.72 | Complete response of multiple melanoma brain metastases after treatment with temozolomide. ( Dvorak, J; Hadzi-Nikolov, D; Melichar, B; Petera, J; Zizka, J, 2004) |
| "Isolated limb infusion (ILI) with temozolomide (TMZ), a novel methylating agent, was performed using a nude rat bearing human melanoma xenograft." | 7.72 | Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. ( Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T, 2004) |
| " 11 (44%) patients showed cerebral metastases prior to therapy with temozolomide." | 7.71 | [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis]. ( Christophers, E; Frick, S; Haacke, TC; Hauschild, A; Lischner, S; Rosien, F; Schäfer, F, 2002) |
| "2 mg/kg three times weekly for 2 weeks (starting on day 1), in combination with oral panobinostat 10, 20, or 30 mg every 96 h (starting on day 8), and oral temozolomide 150 mg/m(2)/day on days 9 through 13." | 6.79 | Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). ( Deutsch, J; Frees, M; Laux, D; Leon-Ferre, R; Milhem, M; Smith, BJ; Xia, C, 2014) |
| "Lomeguatrib, an O(6)-methylguanine-DNA methyltransferase inactivator, was evaluated in an extended dosing regimen with temozolomide, designed according to pharmacodynamic data from previous studies." | 6.74 | A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. ( Abdi, E; Beith, J; Corrie, PG; Kefford, RF; Kotasek, D; Margison, GP; Middleton, MR; Mortimer, P; Palmer, C; Ranson, M; Thomas, NP; Watson, AJ, 2009) |
| " Accordingly, a clinical trial using oral temozolomide (TMZ) and subcutaneous PEG-interferon alpha-2b (PEG) in patients with metastatic melanoma was designed to determine the maximal tolerated dosage of both drugs and the antitumoral response." | 6.73 | Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study. ( Bedane, C; Cupissol, D; Delaunay, M; Dereure, O; Dreno, B; Guillot, B; Khamari, A; Picot, MC, 2008) |
| "Brain metastases are a common complication in patients suffering from metastatic malignant melanoma." | 6.72 | Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. ( Budach, V; Hofmann, M; Kiecker, F; Schlenger, L; Sterry, W; Trefzer, U; Wurm, R, 2006) |
| "Temozolomide is a rapidly absorbed chemotherapeutic agent, achieving significant central nervous system penetration." | 6.72 | Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. ( Hansson, J; Månsson-Brahme, E; Masucci, GV; Nilsson, B; Ragnarsson-Olding, B; Wagenius, G, 2006) |
| " Therefore, the authors initiated a Phase I study to determine the pharmacokinetics and safety profile of temozolomide (TMZ), a novel oral alkylating agent known to cross the blood-brain barrier, in combination with interferon alpha-2b (IFN-alpha2b)." | 6.71 | Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. ( Agarwala, SS; Kirkwood, JM, 2003) |
| "Temozolomide is a well-tolerated oral alkylating agent with activity in the CNS." | 6.71 | Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. ( Agarwala, SS; Atkins, M; Buzaid, A; Czarnetski, B; Dreno, B; Gore, M; Kirkwood, JM; Rankin, EM; Skarlos, D; Thatcher, N, 2004) |
| "Temozolomide is an oral alkylating agent that has equivalent activity to dacarbazine, but it has the advantage of CNS penetration." | 6.71 | A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. ( Anderson, C; Baron, A; Gibbs, P; Gonzalez, R; Lewis, KD; O'Day, S; Richards, J; Russ, P; Weber, J; Zeng, C, 2005) |
| "Temozolomide (TMZ) is a DNA-alkylating agent used for the treatment of glioma, astrocytoma, and melanoma." | 6.47 | A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy. ( Jiang, G; Liu, YQ; Pei, DS; Wei, ZP; Xin, Y; Zheng, JN, 2011) |
| "A novel core‑shell type thermo‑nanoparticle (CSTNP) co‑loaded with temozolomide (TMZ) and the fluorescein new indocyanine green dye IR820 (termed IT‑CSTNPs) was designed and combined with a near‑infrared (NIR) laser to realize its photothermal conversion." | 5.51 | Core‑shell type thermo‑nanoparticles loaded with temozolomide combined with photothermal therapy in melanoma cells. ( Hou, X; Jiang, G; Li, X; Liu, W; Liu, Y; Pang, Y; Yang, C, 2019) |
| "Temozolomide was well tolerated; there were no treatment withdrawals or dose reductions caused by toxicity." | 5.43 | Temozolomide for central nervous system involvement in mycosis fungoides. ( Bird, TG; Child, F; Morris, SL; Wain, EM; Whittaker, S, 2016) |
| "Malignant melanoma is an aggressive, highly lethal dermatological malignancy." | 5.43 | DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines. ( Chen, YP; Feng, SX; Hou, XY; Jiang, G; Jiang, XX; Liu, YQ; Xu, XF; Yang, CS; Yang, M, 2016) |
| "The median time to disease progression was 8 weeks, and the overall survival duration was 26 weeks." | 5.36 | The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma. ( Alvarado, GC; Bedikian, AY; Camacho, LH; Hwu, P; Kim, KB; McIntyre, S; Papadopoulos, NE; Yoon, C, 2010) |
| "Melanoma is the most malignant of skin cancers, highly resistant to chemotherapy and radiotherapy." | 5.35 | Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. ( Bocangel, D; Chada, S; Ekmekcioglu, S; Grimm, EA; Poindexter, N; Ramesh, R; Zheng, M, 2008) |
| "Temozolomide (TMZ) is a methylating agent that spontaneously decomposes into the active metabolite of dacarbazine, the most effective agent for the systemic treatment of melanoma." | 5.34 | Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity. ( Bonmassar, E; Caporali, S; Caporaso, P; D'Atri, S; Falcinelli, S; Pagani, E; Pepponi, R; Turriziani, M, 2007) |
| "Indeed melanomas have proven resistant to apoptosis (type I programmed cell death (PCD)) and consequently to most chemotherapy and immunotherapy." | 5.34 | Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. ( De Neve, N; Gras, T; Kiss, R; Le Mercier, M; Lefranc, F; Mathieu, V; Roland, I; Sauvage, S, 2007) |
| "The ability of treatment to reduce melanoma metastatic spreading and invasion of the extracellular matrix was also tested." | 5.33 | Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. ( Forini, O; Gold, B; Graziani, G; Lacal, PM; Leonetti, C; Li, W; Muzi, A; Ruffini, F; Scarsella, M; Tentori, L; Vergati, M; Zhang, J, 2005) |
| " The aim of this phase I study was to determine the maximum tolerated dose of the combination of TPI 287 and temozolomide in metastatic melanoma." | 5.22 | A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. ( Amaria, RN; Bassett, RL; Bedikian, AY; Cain, S; Davies, MA; Hwu, P; Hwu, WJ; Lecagoonporn, S; McQuade, JL; Patel, SP; Posada, LP, 2016) |
| "We conducted a single-arm phase II multi-institution cooperative group study to assess the antitumor activity and safety profile of the combination of TMZ and the rapamycin derivative everolimus in patients with metastatic unresectable malignant melanoma." | 5.19 | Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. ( Allred, JB; Creagan, ET; Dronca, RS; Kaur, JS; Lieser, EA; Maples, WJ; Marchello, BT; Markovic, SN; Moore, TD; Nevala, WK; Perez, DG; Pockaj, BA; Thompson, M, 2014) |
| "This study showed that temozolomide (150-200 mg/m(2)/day) can safely be given with a PARP inhibitory dose of rucaparib, increasing progression-free survival over historical controls in metastatic melanoma patients." | 5.17 | A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. ( Abbattista, A; Calvert, H; Curtin, N; Dewji, R; Gallo, J; Lorigan, P; Middleton, MR; Mulligan, E; Plummer, R; Scott, L; Steven, N; Wang, D; Wilson, RH, 2013) |
| "The combination of oblimersen, temozolomide, and nab-paclitaxel was well tolerated and demonstrated encouraging activity in patients with advanced melanoma." | 5.17 | Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. ( Chang, J; Cheng, X; Escano, C; Gandhi, A; Kannan, R; Liebes, L; Madden, K; Mendoza, S; Muren, C; Ott, PA; Pavlick, AC; Shao, Y, 2013) |
| "Temozolomide (TMZ) is widely used for chemotherapy of metastatic melanoma." | 5.17 | Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. ( Beumer, JH; Buch, SC; Christner, S; Egorin, MJ; Kirkwood, JM; Lin, Y; Moschos, S; Tarhini, AA; Tawbi, HA, 2013) |
| "Previously untreated metastatic melanoma patients with Eastern Cooperative Oncology Group performance status of two or more were treated with temozolomide 150 mg/m(2) days 1-7 orally and bevacizumab 10 mg/kg body weight i." | 5.16 | First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). ( Cathomas, R; Dummer, R; Gillessen, S; Goldinger, SM; Mamot, C; Michielin, O; Mjhic-Probst, D; Moch, H; Ochsenbein, A; Schläppi, M; Schönewolf, N; Schraml, PH; Seifert, B; Simcock, M; von Moos, R, 2012) |
| "To compare the efficacy of an extended schedule escalated dose of temozolomide versus standard dose dacarbazine in a large population of patients with stage IV melanoma." | 5.15 | Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). ( Agarwala, SS; Becker, J; Conry, R; Davidson, N; Dummer, R; Eggermont, AM; Engelen, K; Hwu, WJ; Keilholz, U; Kruit, WH; Mortier, L; Patel, PM; Punt, CJ; Robert, C; Schadendorf, D; Spatz, A; Suciu, S; Thompson, JA; Trefzer, U, 2011) |
| "This study compared the central nervous system (CNS) metastasis incidence between a temozolomide- and a dacarbazine-based regimen in untreated stage IV melanoma patients." | 5.15 | Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. ( Brugnara, S; Chiarion-Sileni, V; Colucci, G; De Salvo, GL; Del Bianco, P; Guida, M; Pigozzo, J; Ridolfi, L; Ridolfi, R; Romanini, A, 2011) |
| "In a search for more effective combination chemotherapy for the treatment of metastatic melanoma, we conducted a phase I trial of a novel combination of docetaxel, temozolomide, and cisplatin." | 5.14 | Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. ( Bedikian, AY; Camacho, LH; Frost, AM; Hernandez, IM; Hwu, P; Hwu, WJ; Jack, MA; Kim, KB; Ng, C; Papadopoulos, NE, 2009) |
| "Patients must have had stage IV cutaneous melanoma, no active brain metastases, Zubrod PS 0-1, up to 1 prior systemic therapy excluding thalidomide, temozolomide, or dacarbazine, adequate organ function, and given informed consent." | 5.14 | Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. ( Clark, JI; Da Silva, DM; Flaherty, LE; Hutchins, LF; Kast, WM; Liu, PY; Moon, J; Sondak, VK; Sosman, JA; Thompson, JA, 2010) |
| "Preclinical studies show that bortezomib, a proteasome inhibitor, blocks NF-kappaB activation and, combined with temozolomide, enhances activity against human melanoma xenografts and modulates other critical tumor targets." | 5.14 | A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. ( Amiri, KI; Ayers, GD; Horton, LW; Kelley, MC; Koehler, E; Puzanov, I; Richmond, A; Sosman, JA; Su, Y; Yu, Y, 2010) |
| "Temozolomide (TMZ) is a second-generation alkylating agent that has recently shown some efficacy in stage IV melanoma." | 5.14 | Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial. ( Bedane, C; Guillet, G; Guillot, B; Mourey, L; Sassolas, B; Tourani, JM; Wierzbicka-Hainaut, E, 2010) |
| "We conducted a single institution phase II trial to evaluate the tolerability and effectiveness of therapy with arsenic trioxide (ATO) and ascorbic acid (AA) with temozolomide (TMZ) in patients with advanced melanoma." | 5.13 | Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. ( Bael, TE; Gollob, JA; Peterson, BL, 2008) |
| "Our objective was to evaluate the toxicity and antitumor efficacy of concurrent biochemotherapy in metastatic melanoma patients and the effectiveness of adding temozolomide to protect the brain from metastases." | 5.12 | A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study. ( Asna, N; Inbar, MJ; Metser, U; Ron, IG; Ryvo, L; Safra, T; Sapir, EE; Sarid, D; Schneebaum, S, 2006) |
| "Temozolomide and interferon-alpha-2b (IFN-alpha-2b) are both active in melanoma." | 5.12 | Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. ( Aird, S; Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Panageas, KS; Williams, LJ; Wolchok, JD, 2006) |
| "To assess the efficacy and tolerability of extended dose temozolomide and continuous thalidomide in patients with advanced metastatic cutaneous melanoma." | 5.12 | A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. ( Arce-Lara, C; Kloecker, GH; Laber, DA; McMasters, KM; Miller, DM; Okeke, RI; Schonard, CL; Taft, BS, 2006) |
| "Temozolomide is a novel oral alkylating agent, active against metastatic melanoma." | 5.12 | Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma. ( Crespo, C; del Muro, XG; Filipovich, E; García, M; Germà-Lluch, JR; López, JJ; Pérez, X; Rifà, J; Tres, A; Valladares, M, 2006) |
| "The combination of TMZ and celecoxib is safe and potentially effective in the treatment of metastatic melanoma." | 5.12 | Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. ( Fountzilas, G; Frangia, K; Gogas, H; Mantzourani, M; Markopoulos, C; Middleton, M; Panagiotou, P; Papadopoulos, O; Pectasides, D; Polyzos, A; Stavrinidis, I; Tsoutsos, D; Vaiopoulos, G, 2006) |
| "Preliminary studies suggesting that extended-dose temozolomide with thalidomide is safe and active in patients with metastatic melanoma have led to frequent use of this oral regimen." | 5.12 | Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). ( Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D, 2006) |
| "Temozolomide has shown some efficacy in metastatic melanoma and recently received extended approval to treat brain tumours." | 5.12 | Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. ( Egberts, F; Garbe, C; Hauschild, A; Kreissig, M; Linse, R; Mohr, P; Schadendorf, D; Thoelke, A; Tilgen, W; Trefzer, U; Ugurel, S; Vogt, T, 2006) |
| "To evaluate tumor response, pharmacodynamic effects, and safety of a combination of lomeguatrib (LM), an O6-methylguanine DNA-methyltransferase (MGMT) inactivator, and temozolomide (TMZ), TMZ alone, and LM/TMZ after disease progression on TMZ alone in patients with advanced melanoma." | 5.12 | Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. ( Baka, S; Beith, J; Davis, ID; Harris, PA; Haydon, A; Hersey, P; Kefford, RF; Margison, GP; McArthur, GA; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Seebaran, A; Thompson, D; Watson, AJ, 2007) |
| "A multicentre, centrally randomized, open-labelled study with temozolomide and interferon (IFN)-alpha 2b was carried out to study the therapeutic effect in patients with metastatic melanoma stage IV." | 5.11 | Temozolomide and interferon alpha 2b in metastatic melanoma stage IV. ( Fialla, R; Forstinger, Ch; Fritsch, P; Hofmann-Wellenhof, R; Kehrer, H; Kerl, H; Kindermann-Glebowski, E; Klein, G; Koller, J; Konrad, K; Kos, C; Lang, A; Mischer, P; Pachinger, W; Pehamberger, H; Raml, J; Ratzinger, G; Richtig, E; Seeber, A; Smolle, J; Steiner, A; Ulmer, H; Wolff, K; Zelger, B, 2004) |
| "Temozolomide plus thalidomide was an active oral regimen for patients with brain metastases from malignant melanoma." | 5.11 | Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. ( Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Lis, E; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Williams, LJ; Wolchok, JD, 2005) |
| "The present study was designed to assess the efficacy and safety of combination therapy with temozolomide plus cisplatin in patients with metastatic melanoma." | 5.11 | Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial. ( Argon, A; Camlica, H; Tas, F; Topuz, E, 2005) |
| "Temozolomide is an imidazotetrazine with a mechanism of action similar to dacarbazine and equivalent activity in melanoma." | 5.10 | Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. ( Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N, 2003) |
| "Temozolomide is an oral alkylating agent that readily crosses the blood-brain barrier and has activity in patients with advanced melanoma." | 5.10 | A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma. ( Boxall, J; Marples, M; Meyer, T; Napier, MP; Rustin, GJ; Strauss, SJ, 2003) |
| "Temozolomide is a novel oral alkylating agent that is effective against melanoma." | 5.10 | Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. ( Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D, 2002) |
| "To evaluate the antitumor effects and toxicities of whole brain irradiation (WBI) with temozolomide (TMZ) administered by prolonged oral dosing in patients with melanoma metastatic to the brain." | 5.10 | Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. ( Atkins, B; Clark, I; Dutcher, P; Ernstoff, S; Flaherty, L; Gollob, J; II Smith, W; Johnson, D; Longmate, J; Margolin, K; Sosman, J; Thompson, A; Weber, J; Weiss, G, 2002) |
| "To determine the potential economic implications resulting from oral temozolomide (TEM) compared with intravenous (IV) dacarbazine (DTIC) for metastatic melanoma." | 5.09 | Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma. ( Agarwala, S; Hillner, BE; Middleton, MR, 2000) |
| " The authors hereby, evaluated the use of temozolomide (TMZ) for treating metastatic melanoma compared to dacarbazine (DTIC), the effectiveness of TMZ for treating brain metastases, as well as TMZ resistance and how the efficacy of TMZ in malignant melanoma can be increased." | 4.91 | Temozolomide for Treating Malignant Melanoma. ( Hou, XY; Jiang, G; Li, RH; Liu, WL; Liu, YQ; Tang, JQ; Yang, CS, 2015) |
| "Before 2011, dacarbazine and IL-2 were the only FDA approved therapies for metastatic melanoma, and IFN-α is the only approved agent for adjuvant therapy." | 4.90 | Current systemic therapies for melanoma. ( Bordeaux, JS; Koon, HB; Palathinkal, DM; Sharma, TR, 2014) |
| " Two chemotherapeutic regimens are commonly used for the palliative treatment of malignant melanoma: intravenous administration of single-agent dacarbazine or oral administration of temozolomide." | 4.89 | Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients. ( Abdollahi, M; Nikfar, S; Teimouri, F, 2013) |
| "To assess the efficacy of single-agent temozolomide, a standard agent is used for metastatic melanoma in late adjuvant chemotherapy for cutaneous melanoma." | 4.02 | Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma. ( Erturk, K; Tas, F, 2021) |
| "Included patients (aged ≥18 years) had ≥1 prescription for ipilimumab, vemurafenib, temozolomide or dacarbazine between 1 January 2011 and 31 August 2013; diagnosis of melanoma and metastasis before first use (index date); no index drug use prior to the index date; continuous health plan enrollment for ≥6 months before and ≥3 months after index date." | 3.85 | Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States. ( Barber, BL; Batty, N; Chen, YJ; Hines, DM; Ma, Q; Munakata, J; Zhao, Z, 2017) |
| "Isolated limb infusion (ILI) with melphalan (LPAM) or temozolomide (TMZ) was performed on rats bearing melanoma xenografts after systemic administration of the N-cadherin antagonist, ADH-1, or saline." | 3.81 | Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma. ( Augustine, CK; Beasley, GM; Davies, MA; Deng, W; Dewhirst, MW; Fontanella, A; Lidsky, ME; Padussis, JC; Tokuhisa, Y; Toshimitsu, H; Turley, RS; Tyler, DS, 2015) |
| "To investigate the predictive and prognostic value of O(6) -methylguanine DNA methyltransferase (MGMT) inactivation by analyses of promoter methylation in pretreatment tumor biopsies from patients with cutaneous melanoma treated with dacarbazine (DTIC) or temozolomide (TMZ) were performed." | 3.81 | MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma. ( Egyházi Brage, S; Frostvik Stolt, M; Hansson, J; Hertzman Johansson, C; Jewell, R; Johansson, H; Lindén, D; Lindholm, C; Newton-Bishop, J; Snowden, H; Stierner, U; Tuominen, R; van den Oord, JJ; Walker, C; Wolter, P, 2015) |
| "In the present study we collected fresh-frozen pretreatment lymph-node metastasis samples (n=14) from melanoma patients with differential response to dacarbazine (DTIC) or temozolomide (TMZ) chemotherapy, to identify proteins with an impact on treatment response." | 3.80 | Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance. ( Azimi, A; Egyházi Brage, S; Frostvik Stolt, M; Hansson, J; Hertzman Johansson, C; Lehtiö, J; Pernemalm, M, 2014) |
| "Using cell proliferation and DNA methylation assays, FACS analysis and quantitative-RT-PCR we have characterised the response of a panel of NRAS and BRAF mutant melanoma cell lines to various chemotherapy drugs, amongst them dacarbazine (DTIC) and temozolomide (TMZ) and DNA synthesis inhibitors." | 3.80 | Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. ( Arozarena, I; Erice, O; Ferguson, J; Goicoechea, I; Margison, GP; Wellbrock, C, 2014) |
| "The DNA alkylating agent temozolomide (TMZ) is widely used in the treatment of human malignancies such as glioma and melanoma." | 3.78 | Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death. ( Amin, S; Cheng, Y; Huber-Keener, KJ; Liao, J; Ren, X; Sharma, AK; Sk, UH; Sun, YW; Yang, JM; Zhang, L; Zhang, Y, 2012) |
| "Autophagy was measured in tumor biopsies obtained from metastatic melanoma patients enrolled on a phase II trial of temozolomide and sorafenib and correlated to clinical outcome." | 3.77 | Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. ( Amaravadi, RK; Li, LZ; Lum, JJ; Ma, XH; McAfee, QW; Nathanson, KL; Piao, S; Wang, D, 2011) |
| "This study was performed to evaluate the addition of temozolomide (TMZ) to whole brain radiotherapy (WBRT) for brain metastases from melanoma." | 3.76 | Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy? ( Bearden, JD; Behl, D; Brown, PD; Deming, RL; Markovic, SN; Rowland, KM; Sande, JR; Schild, SE, 2010) |
| "All patients with metastatic melanoma treated with either dacarbazine (DTIC) or temozolomide (TMZ) at the British Columbia Cancer Agency (BCCA) from January 1, 1988 to February 1, 2006 were identified through the BCCA pharmacy electronic database, which was then linked to the surveillance and outcomes unit to identify patients with LTS, defined as survival > or =18 months following chemotherapy." | 3.76 | Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide. ( Kim, C; Klasa, R; Kovacic, L; Lee, CW; Savage, KJ; Shah, A, 2010) |
| " A 67-year-old renal transplant recipient developed a nodular malignant melanoma after 30 years of immunosuppression with azathioprine and prednisolone." | 3.75 | Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine. ( Guenova, E; Hoetzenecker, W; Lichte, V; Moehrle, M; Roecken, M; Schaller, M; Woelbing, F, 2009) |
| "Five different human melanoma xenografts were used in a xenograft model of extremity melanoma to evaluate the variability of tumor response to regionally administered melphalan or temozolomide and to determine if various components of pertinent drug resistance pathways for melphalan [glutathione S-transferase (GST)/glutathione] and temozolomide [O(6)-alkylguanine DNA alkyltranferase (AGT)/mismatch repair (MMR)] could be predictive of tumor response." | 3.74 | Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. ( Ali-Osman, F; Augustine, CK; Friedman, HS; Pruitt, SK; Selim, MA; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA, 2007) |
| "Temozolomide is an oral alkylating agent used in the treatment of metastatic melanoma." | 3.74 | Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma. ( Neff, WJ; Nystrom, KK; Pick, AM, 2008) |
| "Clinical trials have shown temozolomide to be an effective agent for treatment of malignant melanoma." | 3.73 | Skin delivery potency and antitumor activities of temozolomide ester prodrugs. ( Conway, BR; Suppasansatorn, P; Wang, G; Wang, W; Wang, Y, 2006) |
| "The aim of this study was to determine the efficacy and tolerability of a biochemotherapy regimen, including low-dose subcutaneous interleukin-2 and temozolomide, in patients with metastatic melanoma." | 3.73 | Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma. ( Carrera, C; Castel, T; Conill, C; Gascón, P; González Cao, M; Herrero, J; Malvehy, J; Martí, R; Martín, M; Mellado, B; Puig, S; Sánchez, M, 2006) |
| "This study investigated whether the therapeutic index of regional melanoma therapy using parenteral temozolomide could be improved by chemomodulation with O6-benzylguanine (O6BG), an inhibitor of the DNA repair enzyme O6-alkylguanine-DNA alkyltransferase (AGT)." | 3.73 | Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. ( Abdel-Wahab, OI; Abdel-Wahab, Z; Augustine, C; Cheng, TY; Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T; Yoshimoto, Y, 2006) |
| "Ten patients with malignant melanoma and phototoxic reactions under dacarbazine or 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC) chemotherapy were investigated." | 3.72 | Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma. ( Geilen, CC; Georgieva, J; Orfanos, CE; Treudler, R, 2004) |
| "The present observation suggests that temozolomide may be an active and well tolerated treatment for malignant melanoma brain metastases." | 3.72 | Complete response of multiple melanoma brain metastases after treatment with temozolomide. ( Dvorak, J; Hadzi-Nikolov, D; Melichar, B; Petera, J; Zizka, J, 2004) |
| "Isolated limb infusion (ILI) with temozolomide (TMZ), a novel methylating agent, was performed using a nude rat bearing human melanoma xenograft." | 3.72 | Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. ( Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T, 2004) |
| " 11 (44%) patients showed cerebral metastases prior to therapy with temozolomide." | 3.71 | [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis]. ( Christophers, E; Frick, S; Haacke, TC; Hauschild, A; Lischner, S; Rosien, F; Schäfer, F, 2002) |
| "Melanoma has been recognized as one of the most immunogenic malignancies; therefore, understanding the mechanisms of tumor-immune interaction is key for developing more efficient treatments." | 2.84 | Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients. ( Dronca, RS; Ivanov, LV; Kottschade, LA; Leontovich, AA; Markovic, SN; Nevala, WK; Thompson, MA, 2017) |
| "2 mg/kg three times weekly for 2 weeks (starting on day 1), in combination with oral panobinostat 10, 20, or 30 mg every 96 h (starting on day 8), and oral temozolomide 150 mg/m(2)/day on days 9 through 13." | 2.79 | Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). ( Deutsch, J; Frees, M; Laux, D; Leon-Ferre, R; Milhem, M; Smith, BJ; Xia, C, 2014) |
| "Temozolomide was administered at a dose of 75 mg/m/day from days 2-6 and subsequent cohorts were dose escalated by 25 mg/m increments." | 2.76 | Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors. ( Lee, FC; Mangalik, A; Movva, S; Parks, V; Rabinowitz, I; Verschraegen, CF, 2011) |
| "Lomeguatrib, an O(6)-methylguanine-DNA methyltransferase inactivator, was evaluated in an extended dosing regimen with temozolomide, designed according to pharmacodynamic data from previous studies." | 2.74 | A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. ( Abdi, E; Beith, J; Corrie, PG; Kefford, RF; Kotasek, D; Margison, GP; Middleton, MR; Mortimer, P; Palmer, C; Ranson, M; Thomas, NP; Watson, AJ, 2009) |
| " Accordingly, a clinical trial using oral temozolomide (TMZ) and subcutaneous PEG-interferon alpha-2b (PEG) in patients with metastatic melanoma was designed to determine the maximal tolerated dosage of both drugs and the antitumoral response." | 2.73 | Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study. ( Bedane, C; Cupissol, D; Delaunay, M; Dereure, O; Dreno, B; Guillot, B; Khamari, A; Picot, MC, 2008) |
| "Brain metastases are a common complication in patients suffering from metastatic malignant melanoma." | 2.72 | Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. ( Budach, V; Hofmann, M; Kiecker, F; Schlenger, L; Sterry, W; Trefzer, U; Wurm, R, 2006) |
| "Temozolomide is a rapidly absorbed chemotherapeutic agent, achieving significant central nervous system penetration." | 2.72 | Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. ( Hansson, J; Månsson-Brahme, E; Masucci, GV; Nilsson, B; Ragnarsson-Olding, B; Wagenius, G, 2006) |
| " Therefore, the authors initiated a Phase I study to determine the pharmacokinetics and safety profile of temozolomide (TMZ), a novel oral alkylating agent known to cross the blood-brain barrier, in combination with interferon alpha-2b (IFN-alpha2b)." | 2.71 | Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. ( Agarwala, SS; Kirkwood, JM, 2003) |
| "Temozolomide is a well-tolerated oral alkylating agent with activity in the CNS." | 2.71 | Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. ( Agarwala, SS; Atkins, M; Buzaid, A; Czarnetski, B; Dreno, B; Gore, M; Kirkwood, JM; Rankin, EM; Skarlos, D; Thatcher, N, 2004) |
| "Temozolomide is an oral alkylating agent that has equivalent activity to dacarbazine, but it has the advantage of CNS penetration." | 2.71 | A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. ( Anderson, C; Baron, A; Gibbs, P; Gonzalez, R; Lewis, KD; O'Day, S; Richards, J; Russ, P; Weber, J; Zeng, C, 2005) |
| " Temozolomide demonstrated linear and reproducible pharmacokinetics and was rapidly absorbed (mean Tmax approximately 1 h) and eliminated (mean t1/2 = 1." | 2.69 | Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. ( Batra, V; Beale, P; Brada, M; Cutler, D; Dugan, M; Judson, I; Moore, S; Reidenberg, P; Statkevich, P, 1999) |
| " We retrieved evidence on treatment-related grade III/IV adverse events, progression-free survival (PFS) and overall survival (OS)." | 2.61 | A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. ( Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM, 2019) |
| "Cutaneous melanoma is the most deadly cutaneous neoplasm." | 2.53 | The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. ( Arnold, A; Braun, R; Dummer, R; Guckenberger, M; Hunger, RE; Lindenblatt, N; Michielin, O; Mihic-Probst, D; Najafi, Y; Siano, M; von Moos, R, 2016) |
| "Brain metastases affect 37% of patients suffering from metastatic melanoma, and their prognosis remains poor, with an overall survival lower than six months." | 2.49 | [Therapeutic strategies and systemic treatment of brain melanoma metastases]. ( Brocard, L; Daste, A; Durando, X; Gimbergues, P; Magné, N; Mansard, S; Thivat, E, 2013) |
| "Temozolomide (TMZ) is a DNA-alkylating agent used for the treatment of glioma, astrocytoma, and melanoma." | 2.47 | A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy. ( Jiang, G; Liu, YQ; Pei, DS; Wei, ZP; Xin, Y; Zheng, JN, 2011) |
| "As long as metastasis is confined to one organ system and is removable, surgery remains the treatment of first choice." | 2.42 | [Therapy of malignant melanoma at the stage of distant metastasis]. ( Eigentler, TK; Garbe, C, 2004) |
| "A novel core‑shell type thermo‑nanoparticle (CSTNP) co‑loaded with temozolomide (TMZ) and the fluorescein new indocyanine green dye IR820 (termed IT‑CSTNPs) was designed and combined with a near‑infrared (NIR) laser to realize its photothermal conversion." | 1.51 | Core‑shell type thermo‑nanoparticles loaded with temozolomide combined with photothermal therapy in melanoma cells. ( Hou, X; Jiang, G; Li, X; Liu, W; Liu, Y; Pang, Y; Yang, C, 2019) |
| "Temozolomide was well tolerated; there were no treatment withdrawals or dose reductions caused by toxicity." | 1.43 | Temozolomide for central nervous system involvement in mycosis fungoides. ( Bird, TG; Child, F; Morris, SL; Wain, EM; Whittaker, S, 2016) |
| "Malignant melanoma is an aggressive, highly lethal dermatological malignancy." | 1.43 | DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines. ( Chen, YP; Feng, SX; Hou, XY; Jiang, G; Jiang, XX; Liu, YQ; Xu, XF; Yang, CS; Yang, M, 2016) |
| "Of clinical relevance, pretreatment of melanoma cells with a mitogen-activated protein kinase pathway inhibitor, which induced G1 arrest, resulted in resistance to temozolomide or bortezomib." | 1.43 | Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells. ( Beaumont, KA; Daignault, SM; Gabrielli, B; Haass, NK; Hill, DS; Lui, GYL; Sharp, DM; Weninger, W, 2016) |
| "We report myelitis with consequent paraplegia as a potential neurological immune-related side effect of ipilimumab." | 1.40 | Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma. ( Ahmad, MW; Alken, S; Colleran, GC; Fitzpatrick, D; Kavanagh, EC; Kelly, CM; Lyons, TG; Murray, B; O'Kane, GM, 2014) |
| "The median time to disease progression was 8 weeks, and the overall survival duration was 26 weeks." | 1.36 | The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma. ( Alvarado, GC; Bedikian, AY; Camacho, LH; Hwu, P; Kim, KB; McIntyre, S; Papadopoulos, NE; Yoon, C, 2010) |
| "Melanoma is the most malignant of skin cancers, highly resistant to chemotherapy and radiotherapy." | 1.35 | Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. ( Bocangel, D; Chada, S; Ekmekcioglu, S; Grimm, EA; Poindexter, N; Ramesh, R; Zheng, M, 2008) |
| "Temozolomide (TMZ) is a methylating agent that spontaneously decomposes into the active metabolite of dacarbazine, the most effective agent for the systemic treatment of melanoma." | 1.34 | Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity. ( Bonmassar, E; Caporali, S; Caporaso, P; D'Atri, S; Falcinelli, S; Pagani, E; Pepponi, R; Turriziani, M, 2007) |
| "Indeed melanomas have proven resistant to apoptosis (type I programmed cell death (PCD)) and consequently to most chemotherapy and immunotherapy." | 1.34 | Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. ( De Neve, N; Gras, T; Kiss, R; Le Mercier, M; Lefranc, F; Mathieu, V; Roland, I; Sauvage, S, 2007) |
| "Sixty four patients with melanoma brain metastases were treated in our department within a 15-year period." | 1.33 | Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome. ( Bafaloukos, DI; Brountzos, EN; Kelekis, DA; Panagiotou, IE; Papathanasiou, MA, 2005) |
| "The ability of treatment to reduce melanoma metastatic spreading and invasion of the extracellular matrix was also tested." | 1.33 | Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. ( Forini, O; Gold, B; Graziani, G; Lacal, PM; Leonetti, C; Li, W; Muzi, A; Ruffini, F; Scarsella, M; Tentori, L; Vergati, M; Zhang, J, 2005) |
| " This study also analyzed the ratio of the toxic effect of TMZ on MNC and on tumor cells (i." | 1.32 | DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system. ( Alvino, E; Bonmassar, L; D'Atri, S; Falcinelli, S; Fuggetta, MP; Guadagni, F; Lacal, PM; Pagani, E; Passarelli, F; Pepponi, R; Prete, SP; Turriziani, M, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.34) | 18.2507 |
| 2000's | 70 (46.98) | 29.6817 |
| 2010's | 71 (47.65) | 24.3611 |
| 2020's | 6 (4.03) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, L | 1 |
| Yang, Y | 1 |
| Si, L | 1 |
| Chi, Z | 1 |
| Sheng, X | 1 |
| Lian, B | 1 |
| Wang, X | 1 |
| Tang, B | 1 |
| Mao, L | 1 |
| Yan, X | 1 |
| Li, S | 1 |
| Bai, X | 1 |
| Guo, J | 1 |
| Cui, C | 1 |
| Lian, W | 1 |
| Zheng, X | 1 |
| Hou, X | 1 |
| Pang, Y | 1 |
| Li, X | 1 |
| Yang, C | 1 |
| Liu, W | 2 |
| Jiang, G | 4 |
| Liu, Y | 1 |
| Franken, MG | 1 |
| Leeneman, B | 1 |
| Gheorghe, M | 1 |
| Uyl-de Groot, CA | 1 |
| Haanen, JBAG | 1 |
| van Baal, PHM | 1 |
| Sahu, P | 1 |
| Kashaw, SK | 1 |
| Sau, S | 1 |
| Kushwah, V | 1 |
| Jain, S | 1 |
| Iyer, AK | 1 |
| Karachaliou, GS | 1 |
| Ayvali, F | 1 |
| Collichio, FA | 1 |
| Lee, CB | 1 |
| Ivanova, A | 1 |
| Ollila, DW | 1 |
| Moschos, SJ | 1 |
| Tas, F | 2 |
| Erturk, K | 1 |
| Dirilenoglu, F | 1 |
| Yukselen, OO | 1 |
| Mocan, G | 1 |
| Niessner, H | 1 |
| Kosnopfel, C | 1 |
| Sinnberg, T | 1 |
| Beck, D | 1 |
| Krieg, K | 1 |
| Wanke, I | 1 |
| Lasithiotakis, K | 1 |
| Bonin, M | 1 |
| Garbe, C | 5 |
| Meier, F | 1 |
| Patel, SP | 3 |
| Kim, DW | 1 |
| Bassett, RL | 2 |
| Cain, S | 3 |
| Washington, E | 1 |
| Hwu, WJ | 8 |
| Kim, KB | 5 |
| Papadopoulos, NE | 4 |
| Homsi, J | 2 |
| Hwu, P | 5 |
| Bedikian, AY | 6 |
| Keidar, M | 1 |
| Yan, D | 1 |
| Beilis, II | 1 |
| Trink, B | 1 |
| Sherman, JH | 1 |
| Donia, M | 1 |
| Ellebaek, E | 1 |
| Øllegaard, TH | 1 |
| Duval, L | 1 |
| Aaby, JB | 1 |
| Hoejberg, L | 1 |
| Køhler, UH | 1 |
| Schmidt, H | 1 |
| Bastholt, L | 1 |
| Svane, IM | 1 |
| Swami, U | 1 |
| Monga, V | 1 |
| Freesmeier, M | 1 |
| Zhang, W | 1 |
| Bossler, AD | 1 |
| Zakharia, Y | 1 |
| Milhem, M | 2 |
| Plummer, R | 1 |
| Lorigan, P | 2 |
| Steven, N | 1 |
| Scott, L | 1 |
| Middleton, MR | 7 |
| Wilson, RH | 1 |
| Mulligan, E | 1 |
| Curtin, N | 1 |
| Wang, D | 2 |
| Dewji, R | 1 |
| Abbattista, A | 1 |
| Gallo, J | 1 |
| Calvert, H | 1 |
| Marcus, DM | 1 |
| Lowe, M | 1 |
| Khan, MK | 1 |
| Lawson, DH | 1 |
| Crocker, IR | 1 |
| Shelton, JW | 1 |
| Melton, A | 1 |
| Maynard, N | 1 |
| Delman, KA | 1 |
| Carlson, GW | 1 |
| Rizzo, M | 1 |
| Teimouri, F | 1 |
| Nikfar, S | 1 |
| Abdollahi, M | 1 |
| Lipson, EJ | 1 |
| Bodell, MA | 1 |
| Kraus, ES | 1 |
| Sharfman, WH | 1 |
| Leccia, MT | 1 |
| Planchamp, F | 1 |
| Sassolas, B | 2 |
| Combemale, P | 1 |
| Modiano, P | 1 |
| Bedane, C | 3 |
| Cupissol, D | 2 |
| Derrey, S | 1 |
| Dygai-Cochet, I | 1 |
| Lamant, L | 1 |
| Lubrano, V | 1 |
| Mirabel, X | 1 |
| Mourrégot, A | 1 |
| Rougé Bugat, ME | 1 |
| Siegrist, S | 1 |
| Thariat, J | 1 |
| Tiffet, O | 1 |
| Truc, G | 1 |
| Verdoni, L | 1 |
| Mazeau-Woynar, V | 1 |
| Meckbach, D | 1 |
| Keim, U | 1 |
| Richter, S | 1 |
| Leiter, U | 2 |
| Eigentler, TK | 2 |
| Bauer, J | 1 |
| Pflugfelder, A | 1 |
| Büttner, P | 1 |
| Weide, B | 1 |
| Megahed, AI | 1 |
| Koon, HB | 2 |
| Walker, MS | 1 |
| Reyes, C | 1 |
| Kerr, J | 1 |
| Satram-Hoang, S | 1 |
| Stepanski, EJ | 1 |
| Turley, RS | 1 |
| Tokuhisa, Y | 1 |
| Toshimitsu, H | 1 |
| Lidsky, ME | 1 |
| Padussis, JC | 1 |
| Fontanella, A | 1 |
| Deng, W | 1 |
| Augustine, CK | 4 |
| Beasley, GM | 2 |
| Davies, MA | 3 |
| Dewhirst, MW | 1 |
| Tyler, DS | 6 |
| Azimi, A | 1 |
| Pernemalm, M | 1 |
| Frostvik Stolt, M | 2 |
| Hansson, J | 3 |
| Lehtiö, J | 1 |
| Egyházi Brage, S | 2 |
| Hertzman Johansson, C | 2 |
| Alrwas, A | 1 |
| Deburr, TL | 1 |
| Bassett, R | 1 |
| Woodman, SE | 1 |
| Arozarena, I | 1 |
| Goicoechea, I | 1 |
| Erice, O | 1 |
| Ferguson, J | 1 |
| Margison, GP | 3 |
| Wellbrock, C | 1 |
| Xia, C | 1 |
| Leon-Ferre, R | 1 |
| Laux, D | 1 |
| Deutsch, J | 1 |
| Smith, BJ | 1 |
| Frees, M | 1 |
| Palathinkal, DM | 1 |
| Sharma, TR | 1 |
| Bordeaux, JS | 1 |
| Speicher, P | 1 |
| Dolber, PC | 1 |
| Peterson, BL | 2 |
| Sharma, K | 1 |
| Mosca, PJ | 1 |
| Royal, R | 1 |
| Ross, M | 1 |
| Zager, JS | 1 |
| Tuominen, R | 1 |
| Jewell, R | 1 |
| van den Oord, JJ | 1 |
| Wolter, P | 1 |
| Stierner, U | 1 |
| Lindholm, C | 1 |
| Lindén, D | 1 |
| Johansson, H | 1 |
| Walker, C | 1 |
| Snowden, H | 1 |
| Newton-Bishop, J | 1 |
| O'Kane, GM | 1 |
| Lyons, TG | 1 |
| Colleran, GC | 1 |
| Ahmad, MW | 1 |
| Alken, S | 1 |
| Kavanagh, EC | 1 |
| Fitzpatrick, D | 1 |
| Murray, B | 1 |
| Kelly, CM | 1 |
| Armstrong, JL | 1 |
| Hill, DS | 2 |
| McKee, CS | 1 |
| Hernandez-Tiedra, S | 1 |
| Lorente, M | 1 |
| Lopez-Valero, I | 1 |
| Eleni Anagnostou, M | 1 |
| Babatunde, F | 1 |
| Corazzari, M | 1 |
| Redfern, CPF | 1 |
| Velasco, G | 1 |
| Lovat, PE | 1 |
| Fico, A | 1 |
| Alfano, D | 1 |
| Valentino, A | 1 |
| Vasta, V | 1 |
| Cavalcanti, E | 1 |
| Travali, S | 1 |
| Patriarca, EJ | 1 |
| Caputo, E | 1 |
| Chang, CL | 1 |
| Schabert, VF | 1 |
| Munakata, J | 2 |
| Donga, P | 1 |
| Abhyankar, S | 1 |
| Reyes, CM | 1 |
| Yim, YM | 1 |
| Bird, TG | 1 |
| Whittaker, S | 1 |
| Wain, EM | 1 |
| Child, F | 1 |
| Morris, SL | 1 |
| Li, RH | 1 |
| Hou, XY | 2 |
| Yang, CS | 2 |
| Liu, WL | 1 |
| Tang, JQ | 1 |
| Liu, YQ | 3 |
| Dummer, R | 6 |
| Siano, M | 1 |
| Hunger, RE | 1 |
| Lindenblatt, N | 1 |
| Braun, R | 1 |
| Michielin, O | 2 |
| Mihic-Probst, D | 1 |
| von Moos, R | 2 |
| Najafi, Y | 1 |
| Guckenberger, M | 1 |
| Arnold, A | 1 |
| Chen, YP | 1 |
| Jiang, XX | 1 |
| Yang, M | 1 |
| Xu, XF | 1 |
| Feng, SX | 1 |
| Beaumont, KA | 1 |
| Daignault, SM | 1 |
| Lui, GYL | 1 |
| Sharp, DM | 1 |
| Gabrielli, B | 1 |
| Weninger, W | 1 |
| Haass, NK | 1 |
| McQuade, JL | 1 |
| Posada, LP | 1 |
| Lecagoonporn, S | 1 |
| Amaria, RN | 1 |
| Schadendorf, D | 4 |
| Hauschild, A | 4 |
| Robert, C | 2 |
| Hamid, O | 1 |
| Daud, A | 1 |
| van den Eertwegh, A | 1 |
| Cranmer, L | 1 |
| O'Day, S | 2 |
| Puzanov, I | 2 |
| Schachter, J | 1 |
| Blank, C | 1 |
| Salama, A | 1 |
| Loquai, C | 1 |
| Mehnert, JM | 1 |
| Hille, D | 1 |
| Ebbinghaus, S | 1 |
| Kang, SP | 1 |
| Zhou, W | 1 |
| Ribas, A | 2 |
| Leontovich, AA | 1 |
| Dronca, RS | 2 |
| Nevala, WK | 2 |
| Thompson, MA | 1 |
| Kottschade, LA | 2 |
| Ivanov, LV | 1 |
| Markovic, SN | 4 |
| Ling, B | 1 |
| Michel, D | 1 |
| Sakharkar, MK | 1 |
| Yang, J | 2 |
| Ryabaya, OO | 1 |
| Inshakov, AN | 1 |
| Egorova, AV | 1 |
| Emelyanova, MA | 1 |
| Nasedkina, TV | 1 |
| Zasedatelev, AS | 1 |
| Khochenkov, DA | 1 |
| Stepanova, EV | 1 |
| Ma, Q | 1 |
| Chen, YJ | 1 |
| Hines, DM | 1 |
| Batty, N | 1 |
| Barber, BL | 1 |
| Zhao, Z | 1 |
| Tarhini, AA | 2 |
| Kirkwood, JM | 6 |
| Gooding, WE | 1 |
| Moschos, S | 2 |
| Agarwala, SS | 5 |
| Camacho, LH | 2 |
| Ng, C | 1 |
| Hernandez, IM | 1 |
| Frost, AM | 1 |
| Jack, MA | 1 |
| Zheng, M | 1 |
| Bocangel, D | 1 |
| Ramesh, R | 1 |
| Ekmekcioglu, S | 1 |
| Poindexter, N | 1 |
| Grimm, EA | 1 |
| Chada, S | 1 |
| Guzel, A | 1 |
| Maciaczyk, J | 1 |
| Dohmen-Scheufler, H | 1 |
| Senturk, S | 1 |
| Volk, B | 1 |
| Ostertag, CB | 1 |
| Nikkhah, G | 1 |
| Zaja-Milatovic, S | 1 |
| Thu, YM | 1 |
| Lee, F | 1 |
| Smykla, R | 1 |
| Richmond, A | 2 |
| Kefford, RF | 2 |
| Thomas, NP | 1 |
| Corrie, PG | 1 |
| Palmer, C | 1 |
| Abdi, E | 1 |
| Kotasek, D | 1 |
| Beith, J | 2 |
| Ranson, M | 3 |
| Mortimer, P | 2 |
| Watson, AJ | 2 |
| Cubitt, CL | 1 |
| Zhang, S | 1 |
| Munster, PN | 1 |
| Yu, H | 1 |
| Sullivan, DM | 1 |
| Jove, R | 1 |
| Messina, JL | 1 |
| Daud, AI | 2 |
| Guenova, E | 1 |
| Lichte, V | 1 |
| Hoetzenecker, W | 1 |
| Woelbing, F | 1 |
| Moehrle, M | 1 |
| Roecken, M | 1 |
| Schaller, M | 1 |
| Clark, JI | 1 |
| Moon, J | 1 |
| Hutchins, LF | 1 |
| Sosman, JA | 2 |
| Kast, WM | 1 |
| Da Silva, DM | 1 |
| Liu, PY | 1 |
| Thompson, JA | 2 |
| Flaherty, LE | 1 |
| Sondak, VK | 1 |
| Yoon, C | 1 |
| McIntyre, S | 1 |
| Alvarado, GC | 1 |
| Su, Y | 1 |
| Amiri, KI | 1 |
| Horton, LW | 1 |
| Yu, Y | 1 |
| Ayers, GD | 1 |
| Koehler, E | 1 |
| Kelley, MC | 1 |
| Schild, SE | 1 |
| Behl, D | 1 |
| Brown, PD | 1 |
| Sande, JR | 1 |
| Deming, RL | 1 |
| Rowland, KM | 1 |
| Bearden, JD | 1 |
| Wierzbicka-Hainaut, E | 1 |
| Mourey, L | 1 |
| Guillot, B | 2 |
| Guillet, G | 1 |
| Tourani, JM | 1 |
| Guenterberg, KD | 1 |
| Grignol, VP | 1 |
| Raig, ET | 1 |
| Zimmerer, JM | 1 |
| Chan, AN | 1 |
| Blaskovits, FM | 1 |
| Young, GS | 1 |
| Nuovo, GJ | 1 |
| Mundy, BL | 1 |
| Lesinski, GB | 1 |
| Carson, WE | 1 |
| Kim, C | 1 |
| Lee, CW | 1 |
| Kovacic, L | 1 |
| Shah, A | 1 |
| Klasa, R | 1 |
| Savage, KJ | 1 |
| Osmond, GW | 1 |
| Zipfel, PA | 2 |
| Padussis, J | 1 |
| Harlan, E | 1 |
| Davis, MD | 1 |
| Pittelkow, MR | 1 |
| Fateh, S | 1 |
| Schell, TD | 1 |
| Gingrich, R | 1 |
| Neves, RI | 1 |
| Drabick, JJ | 1 |
| Zuckerman, JE | 1 |
| Hsueh, T | 1 |
| Koya, RC | 1 |
| Davis, ME | 1 |
| Movva, S | 1 |
| Verschraegen, CF | 1 |
| Rabinowitz, I | 1 |
| Mangalik, A | 1 |
| Parks, V | 1 |
| Lee, FC | 1 |
| Ma, XH | 1 |
| Piao, S | 1 |
| McAfee, QW | 1 |
| Nathanson, KL | 1 |
| Lum, JJ | 1 |
| Li, LZ | 1 |
| Amaravadi, RK | 1 |
| Wei, ZP | 1 |
| Pei, DS | 1 |
| Xin, Y | 1 |
| Zheng, JN | 1 |
| Seifert, B | 1 |
| Simcock, M | 1 |
| Goldinger, SM | 1 |
| Gillessen, S | 1 |
| Ochsenbein, A | 1 |
| Cathomas, R | 1 |
| Schläppi, M | 1 |
| Moch, H | 1 |
| Schraml, PH | 1 |
| Mjhic-Probst, D | 1 |
| Mamot, C | 1 |
| Schönewolf, N | 1 |
| Soon, CW | 1 |
| Algazi, AP | 1 |
| Cha, EN | 1 |
| Webb, EM | 1 |
| Patel, PM | 1 |
| Suciu, S | 1 |
| Mortier, L | 1 |
| Kruit, WH | 1 |
| Trefzer, U | 3 |
| Punt, CJ | 1 |
| Davidson, N | 1 |
| Becker, J | 1 |
| Conry, R | 1 |
| Engelen, K | 1 |
| Keilholz, U | 1 |
| Eggermont, AM | 1 |
| Spatz, A | 1 |
| Chiarion-Sileni, V | 1 |
| Guida, M | 1 |
| Ridolfi, L | 1 |
| Romanini, A | 1 |
| Del Bianco, P | 1 |
| Pigozzo, J | 1 |
| Brugnara, S | 1 |
| Colucci, G | 1 |
| Ridolfi, R | 1 |
| De Salvo, GL | 1 |
| Handler, MZ | 1 |
| Mruthyunjaya, P | 1 |
| Nelson, K | 1 |
| Boulinguez, S | 1 |
| Salameire, D | 1 |
| Hong, M | 1 |
| Puaux, AL | 1 |
| Huang, C | 1 |
| Loumagne, L | 1 |
| Tow, C | 1 |
| Mackay, C | 1 |
| Kato, M | 1 |
| Prévost-Blondel, A | 1 |
| Avril, MF | 1 |
| Nardin, A | 1 |
| Abastado, JP | 1 |
| Stark, MS | 1 |
| Woods, SL | 1 |
| Gartside, MG | 1 |
| Bonazzi, VF | 1 |
| Dutton-Regester, K | 1 |
| Aoude, LG | 1 |
| Chow, D | 1 |
| Sereduk, C | 1 |
| Niemi, NM | 1 |
| Tang, N | 1 |
| Ellis, JJ | 1 |
| Reid, J | 1 |
| Zismann, V | 1 |
| Tyagi, S | 1 |
| Muzny, D | 1 |
| Newsham, I | 1 |
| Wu, Y | 1 |
| Palmer, JM | 1 |
| Pollak, T | 1 |
| Youngkin, D | 1 |
| Brooks, BR | 1 |
| Lanagan, C | 1 |
| Schmidt, CW | 1 |
| Kobe, B | 1 |
| MacKeigan, JP | 1 |
| Yin, H | 1 |
| Brown, KM | 1 |
| Gibbs, R | 1 |
| Trent, J | 1 |
| Hayward, NK | 1 |
| Cheng, Y | 1 |
| Sk, UH | 1 |
| Zhang, Y | 1 |
| Ren, X | 1 |
| Zhang, L | 1 |
| Huber-Keener, KJ | 1 |
| Sun, YW | 1 |
| Liao, J | 1 |
| Amin, S | 1 |
| Sharma, AK | 1 |
| Yang, JM | 1 |
| Luo, Y | 2 |
| Ellis, LZ | 1 |
| Dallaglio, K | 2 |
| Takeda, M | 1 |
| Robinson, WA | 2 |
| Robinson, SE | 2 |
| Lewis, KD | 2 |
| McCarter, MD | 2 |
| Gonzalez, R | 3 |
| Norris, DA | 2 |
| Roop, DR | 2 |
| Spritz, RA | 1 |
| Ahn, NG | 1 |
| Fujita, M | 2 |
| Chen, Y | 1 |
| Wang, J | 1 |
| Thompson, DC | 1 |
| Vasiliou, V | 1 |
| Durando, X | 1 |
| Mansard, S | 1 |
| Daste, A | 1 |
| Gimbergues, P | 1 |
| Brocard, L | 1 |
| Magné, N | 1 |
| Thivat, E | 1 |
| Suman, VJ | 1 |
| Perez, DG | 2 |
| McWilliams, RR | 1 |
| Kaur, JS | 2 |
| Amatruda, TT | 1 |
| Geoffroy, FJ | 1 |
| Gross, HM | 1 |
| Cohen, PA | 1 |
| Jaslowski, AJ | 1 |
| Kosel, ML | 1 |
| Gilbertson, RJ | 1 |
| Graham, TA | 1 |
| Ott, PA | 1 |
| Chang, J | 1 |
| Madden, K | 1 |
| Kannan, R | 1 |
| Muren, C | 1 |
| Escano, C | 1 |
| Cheng, X | 1 |
| Shao, Y | 1 |
| Mendoza, S | 1 |
| Gandhi, A | 1 |
| Liebes, L | 1 |
| Pavlick, AC | 1 |
| Keir, ST | 1 |
| Friedman, HS | 4 |
| Reardon, DA | 1 |
| Bigner, DD | 1 |
| Gray, LA | 1 |
| Tawbi, HA | 1 |
| Beumer, JH | 1 |
| Buch, SC | 1 |
| Egorin, MJ | 1 |
| Lin, Y | 1 |
| Christner, S | 1 |
| Allred, JB | 1 |
| Lieser, EA | 1 |
| Thompson, M | 1 |
| Maples, WJ | 1 |
| Creagan, ET | 1 |
| Pockaj, BA | 1 |
| Moore, TD | 1 |
| Marchello, BT | 1 |
| Frick, S | 1 |
| Lischner, S | 1 |
| Rosien, F | 1 |
| Haacke, TC | 1 |
| Schäfer, F | 1 |
| Christophers, E | 1 |
| Conill, C | 3 |
| Puig, S | 3 |
| Toscas, I | 1 |
| Castel, T | 3 |
| Dréno, B | 3 |
| Wallon-Dumont, G | 1 |
| de Gast, GC | 1 |
| Batchelor, D | 1 |
| Kersten, MJ | 1 |
| Vyth-Dreese, FA | 1 |
| Sein, J | 1 |
| van de Kasteele, WF | 1 |
| Nooijen, WJ | 1 |
| Nieweg, OE | 1 |
| de Waal, MA | 1 |
| Boogerd, W | 1 |
| Pagani, E | 2 |
| Pepponi, R | 2 |
| Fuggetta, MP | 1 |
| Prete, SP | 1 |
| Turriziani, M | 2 |
| Bonmassar, L | 1 |
| Lacal, PM | 2 |
| Falcinelli, S | 2 |
| Passarelli, F | 1 |
| Guadagni, F | 1 |
| Alvino, E | 1 |
| D'Atri, S | 2 |
| Danson, S | 1 |
| Arance, A | 1 |
| Clamp, A | 1 |
| Hodgetts, J | 1 |
| Lomax, L | 1 |
| Ashcroft, L | 1 |
| Thatcher, N | 2 |
| Strauss, SJ | 1 |
| Marples, M | 1 |
| Napier, MP | 1 |
| Meyer, T | 1 |
| Boxall, J | 1 |
| Rustin, GJ | 1 |
| Kiebert, GM | 1 |
| Jonas, DL | 1 |
| Oubre, DN | 1 |
| Harkness, KA | 1 |
| Manford, MR | 1 |
| González-Cao, M | 1 |
| Jorcano, S | 1 |
| Malvehy, J | 2 |
| Martí, R | 2 |
| Treudler, R | 1 |
| Georgieva, J | 1 |
| Geilen, CC | 1 |
| Orfanos, CE | 1 |
| Dvorak, J | 1 |
| Melichar, B | 1 |
| Zizka, J | 1 |
| Hadzi-Nikolov, D | 1 |
| Petera, J | 1 |
| Gore, M | 1 |
| Czarnetski, B | 1 |
| Atkins, M | 1 |
| Buzaid, A | 1 |
| Skarlos, D | 2 |
| Rankin, EM | 1 |
| Richtig, E | 1 |
| Hofmann-Wellenhof, R | 1 |
| Pehamberger, H | 1 |
| Forstinger, Ch | 1 |
| Wolff, K | 1 |
| Mischer, P | 1 |
| Raml, J | 1 |
| Fritsch, P | 1 |
| Zelger, B | 1 |
| Ratzinger, G | 1 |
| Koller, J | 1 |
| Lang, A | 1 |
| Konrad, K | 1 |
| Kindermann-Glebowski, E | 1 |
| Seeber, A | 1 |
| Steiner, A | 1 |
| Fialla, R | 1 |
| Pachinger, W | 1 |
| Kos, C | 1 |
| Klein, G | 1 |
| Kehrer, H | 1 |
| Kerl, H | 1 |
| Ulmer, H | 1 |
| Smolle, J | 1 |
| Gogas, H | 3 |
| Bafaloukos, D | 2 |
| Ueno, T | 2 |
| Ko, SH | 2 |
| Grubbs, E | 2 |
| Pruitt, SK | 3 |
| Harting, MS | 1 |
| Buzaid, AC | 2 |
| Panagiotou, IE | 1 |
| Brountzos, EN | 1 |
| Kelekis, DA | 1 |
| Papathanasiou, MA | 1 |
| Bafaloukos, DI | 1 |
| Lis, E | 1 |
| Menell, JH | 2 |
| Panageas, KS | 2 |
| Lamb, LA | 2 |
| Merrell, J | 1 |
| Williams, LJ | 2 |
| Krown, SE | 3 |
| Chapman, PB | 2 |
| Livingston, PO | 2 |
| Wolchok, JD | 2 |
| Houghton, AN | 3 |
| Gibbs, P | 1 |
| Richards, J | 2 |
| Weber, J | 2 |
| Anderson, C | 1 |
| Zeng, C | 1 |
| Baron, A | 1 |
| Russ, P | 1 |
| Hofmann, M | 1 |
| Kiecker, F | 1 |
| Wurm, R | 1 |
| Schlenger, L | 1 |
| Budach, V | 1 |
| Sterry, W | 1 |
| Tani, M | 1 |
| Fina, M | 1 |
| Alinari, L | 1 |
| Stefoni, V | 1 |
| Baccarani, M | 1 |
| Zinzani, PL | 1 |
| Tentori, L | 1 |
| Leonetti, C | 1 |
| Scarsella, M | 1 |
| Muzi, A | 1 |
| Vergati, M | 1 |
| Forini, O | 1 |
| Ruffini, F | 1 |
| Gold, B | 1 |
| Li, W | 1 |
| Zhang, J | 1 |
| Graziani, G | 1 |
| Argon, A | 1 |
| Camlica, H | 1 |
| Topuz, E | 1 |
| Mori, T | 1 |
| O'Day, SJ | 1 |
| Umetani, N | 1 |
| Martinez, SR | 1 |
| Kitago, M | 1 |
| Koyanagi, K | 1 |
| Kuo, C | 1 |
| Takeshima, TL | 1 |
| Milford, R | 1 |
| Wang, HJ | 1 |
| Vu, VD | 1 |
| Nguyen, SL | 1 |
| Hoon, DS | 1 |
| Suppasansatorn, P | 2 |
| Wang, G | 1 |
| Conway, BR | 2 |
| Wang, W | 1 |
| Wang, Y | 2 |
| González Cao, M | 1 |
| Sánchez, M | 1 |
| Martín, M | 1 |
| Carrera, C | 1 |
| Herrero, J | 1 |
| Gascón, P | 1 |
| Mellado, B | 1 |
| Ron, IG | 1 |
| Sarid, D | 1 |
| Ryvo, L | 1 |
| Sapir, EE | 1 |
| Schneebaum, S | 1 |
| Metser, U | 1 |
| Asna, N | 1 |
| Inbar, MJ | 1 |
| Safra, T | 1 |
| Yoshimoto, Y | 2 |
| Augustine, C | 1 |
| Abdel-Wahab, Z | 1 |
| Cheng, TY | 1 |
| Abdel-Wahab, OI | 1 |
| Aird, S | 1 |
| Laber, DA | 1 |
| Okeke, RI | 1 |
| Arce-Lara, C | 1 |
| Taft, BS | 1 |
| Schonard, CL | 1 |
| McMasters, KM | 1 |
| Kloecker, GH | 1 |
| Miller, DM | 1 |
| Schmutz, JL | 1 |
| Barbaud, A | 1 |
| Trechot, P | 1 |
| Masucci, GV | 1 |
| Månsson-Brahme, E | 1 |
| Ragnarsson-Olding, B | 1 |
| Nilsson, B | 1 |
| Wagenius, G | 1 |
| García, M | 1 |
| del Muro, XG | 1 |
| Tres, A | 1 |
| Crespo, C | 1 |
| Valladares, M | 1 |
| López, JJ | 1 |
| Rifà, J | 1 |
| Pérez, X | 1 |
| Filipovich, E | 1 |
| Germà-Lluch, JR | 1 |
| Polyzos, A | 1 |
| Stavrinidis, I | 1 |
| Frangia, K | 1 |
| Tsoutsos, D | 1 |
| Panagiotou, P | 1 |
| Markopoulos, C | 1 |
| Papadopoulos, O | 1 |
| Pectasides, D | 1 |
| Mantzourani, M | 1 |
| Middleton, M | 1 |
| Vaiopoulos, G | 1 |
| Fountzilas, G | 2 |
| Niedzwiecki, D | 1 |
| Hodgson, L | 1 |
| Haluska, FG | 1 |
| Ugurel, S | 2 |
| Thoelke, A | 1 |
| Egberts, F | 1 |
| Kreissig, M | 1 |
| Linse, R | 1 |
| Vogt, T | 1 |
| Tilgen, W | 2 |
| Mohr, P | 1 |
| Caporaso, P | 1 |
| Caporali, S | 1 |
| Bonmassar, E | 1 |
| Yoo, JS | 1 |
| Selim, MA | 1 |
| Ali-Osman, F | 1 |
| Mathieu, V | 1 |
| Le Mercier, M | 1 |
| De Neve, N | 1 |
| Sauvage, S | 1 |
| Gras, T | 1 |
| Roland, I | 1 |
| Lefranc, F | 1 |
| Kiss, R | 1 |
| Hersey, P | 1 |
| Thompson, D | 1 |
| McArthur, GA | 1 |
| Haydon, A | 1 |
| Davis, ID | 1 |
| Harris, PA | 1 |
| Baka, S | 1 |
| Seebaran, A | 1 |
| Sabharwal, A | 1 |
| Nimmannit, U | 1 |
| Du, L | 1 |
| Quirin, C | 1 |
| Mainka, A | 1 |
| Hesse, A | 1 |
| Nettelbeck, DM | 1 |
| Fontijn, D | 1 |
| Adema, AD | 1 |
| Bhakat, KK | 1 |
| Pinedo, HM | 1 |
| Peters, GJ | 1 |
| Boven, E | 1 |
| Karakis, I | 1 |
| McGeeney, B | 1 |
| Demierre, MF | 1 |
| Thiele, JJ | 1 |
| Wolpowitz, D | 1 |
| Bhawan, J | 1 |
| Spieth, K | 1 |
| Kaufmann, R | 1 |
| Becker, JC | 1 |
| Beyeler, M | 1 |
| Bröcker, EB | 1 |
| Kaehler, KC | 1 |
| Pföhler, C | 1 |
| Gille, J | 1 |
| Testori, A | 1 |
| Whitman, E | 1 |
| Mann, GB | 1 |
| Lutzky, J | 1 |
| Camacho, L | 1 |
| Parmiani, G | 1 |
| Tosti, G | 1 |
| Hoos, A | 1 |
| Yuh, L | 1 |
| Gupta, R | 1 |
| Srivastava, PK | 1 |
| Pick, AM | 1 |
| Neff, WJ | 1 |
| Nystrom, KK | 1 |
| Khamari, A | 1 |
| Delaunay, M | 1 |
| Picot, MC | 1 |
| Dereure, O | 1 |
| Bael, TE | 1 |
| Gollob, JA | 1 |
| Dehart, WK | 1 |
| Gilliam, AC | 1 |
| Lu, KQ | 1 |
| Brell, J | 1 |
| Anderson, CM | 1 |
| Legha, SS | 1 |
| Brada, M | 1 |
| Judson, I | 1 |
| Beale, P | 1 |
| Moore, S | 1 |
| Reidenberg, P | 1 |
| Statkevich, P | 1 |
| Dugan, M | 1 |
| Batra, V | 1 |
| Cutler, D | 1 |
| Hillner, BE | 1 |
| Agarwala, S | 1 |
| Cohen, MH | 1 |
| Johnson, JR | 1 |
| Burg, G | 1 |
| Biasco, G | 1 |
| Pantaleo, MA | 1 |
| Casadei, S | 1 |
| Georgoulias, V | 1 |
| Briassoulis, E | 1 |
| Samantas, E | 1 |
| Kalofonos, Ch | 1 |
| Karabelis, A | 1 |
| Kosmidis, P | 1 |
| Margolin, K | 1 |
| Atkins, B | 1 |
| Thompson, A | 1 |
| Ernstoff, S | 1 |
| Flaherty, L | 1 |
| Clark, I | 1 |
| Weiss, G | 1 |
| Sosman, J | 1 |
| II Smith, W | 1 |
| Dutcher, P | 1 |
| Gollob, J | 1 |
| Longmate, J | 1 |
| Johnson, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2 Study of Apatinib Combined With Temozolomide in the Treatment of Advanced Melanoma Patients After Conventional Treatment Failure[NCT03422445] | Phase 2 | 30 participants (Anticipated) | Interventional | 2018-01-08 | Recruiting | ||
| Phase Ib/II: Epigenetic Modification of Chemosensitivity and Apoptosis in Metastatic Melanoma: Treatment of a Resistant Disease Using Decitabine, Temozolomide and Panobinostat[NCT00925132] | Phase 1/Phase 2 | 39 participants (Actual) | Interventional | 2009-12-31 | Terminated (stopped due to Change in the number of approved drugs for metastatic melanoma) | ||
| Randomized, Phase II Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Patients With Advanced Melanoma (KEYNOTE 002)[NCT01704287] | Phase 2 | 540 participants (Actual) | Interventional | 2012-11-20 | Completed | ||
| A Phase II Trial of Combination Thalidomide Plus Temozolomide in Patients With Metastatic Malignant Melanoma[NCT00104988] | Phase 2 | 64 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Phase I Study of the Combination of Axitinib (AX) Plus Everolimus (EV) in Patients With Malignant Advanced Solid Tumors[NCT01334073] | Phase 1 | 19 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System[NCT00068666] | Phase 2 | 41 participants (Actual) | Interventional | 2004-01-31 | Terminated | ||
| A Prospective Phase II Study in Patients With Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era[NCT03138642] | Phase 2 | 30 participants (Anticipated) | Interventional | 2010-07-01 | Recruiting | ||
| Temozolomide Combined With Bevacizumab in Metastatic Melanoma. A Multicenter Phase II Trial[NCT00568048] | Phase 2 | 62 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Extended Schedule, Escalated Dose Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group[NCT00091572] | Phase 3 | 859 participants (Actual) | Interventional | 2004-10-20 | Completed | ||
| Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination: Post-Operative Adjuvant Ganglioside GM2-KLH/QS-21 (BMS-248479) Vaccination Treatment After Resection of Primary Cutaneous Melanoma Thicker Than 1.5mm (AJCC/UICC Stage II, T3-T4N0M0), a 2-Arm Multicenter Rand[NCT00005052] | Phase 3 | 0 participants | Interventional | 1999-12-31 | Active, not recruiting | ||
| A Randomized Phase II Trial of Temozolomide (TMZ) and Bevacizumab or ABI-007 (ABX)/Carboplatin (CBDCA) and Bevacizumab in Patients With Unresectable Stage IV Malignant Melanoma[NCT00626405] | Phase 2 | 95 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma[NCT00521001] | Phase 2 | 49 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| Phase I-II Study of the Combination Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation[NCT01959633] | Phase 1/Phase 2 | 11 participants (Actual) | Interventional | 2014-04-03 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Tumor response rate was assessed using RECIST criteria in which a complete response was the disappearance of all target lesions; Partial response was a 30% decrease in the sum of the longest dimension (LD) of target lesions, relative to baseline measurement; Progressive disease was an increase of 20% or more in the sum of the LD of target lesions; and Stable disease was a decrease in tumor size of less than 30% or increase of less than 20%.~Tumor response rate was also assessed using CHOI's criteria in which a response was a 10% decrease in tumor size or a 15% decrease in tumor density on contrast-enhanced computed tomography scan.~Tumor response rates were assessed in order to determine effectiveness of the treatment regimen which was defined by the response rate of at least 30% as measured by either the RECIST or Choi's criteria, and ineffective if the rate is less than 15% on both." (NCT00925132)
Timeframe: 12 weeks (2 cycles)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Progressive Disease (PD) | Stable Disease (SD) | |
| Phase II:Decitabine 0.2 mg/kg +Panobinostat 30mg +Temozolomide | 12 | 5 |
"A DLT was any Grade 4 toxicity for neutrophils or platelets for ≥ 7 days, Grade 3 toxicity for neutrophils for ≥ 21 days, any Grade 3 solid organ toxicity not explainable by another cause (e.g. neurotoxicity, GI toxicity), metabolic/laboratory toxicity (≥10 x ULN AST) for ≥ 14 days, any Grade 4 infection or QTcF> 500msec EKG. DLTs were assessed according to the Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0.~All adverse events were collected and graded to determine DLTs as assessed according to the Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0. DLTs were assessed to determine the recommended Decitabine and Panobinostat dose for the Phase II portion of the trial." (NCT00925132)
Timeframe: 6 weeks (one full cycle)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Cohort 1: Experienced DLT | Cohort 2: Experienced DLT | Cohort 3: Experienced DLT | Cohort 4: Experienced DLT | |
| Phase I Dose Escalation | 0 | 0 | 0 | 0 |
For participants who demonstrated a confirmed response (Complete Response [CR]: disappearance of all target lesions or Partial Response [PR]: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until disease progression or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. DOR analysis was based on IRO assessment. Analysis of DOR was not planned or analyzed for the switch-to-pembrolizumab treatment groups. Median DOR for participants who demonstrated a confirmed response is presented. (NCT01704287)
Timeframe: Up to approximately 36 months (Through Final Analysis database cutoff date of 16-Nov-2015)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab 2 mg/kg | 22.8 |
| Pembrolizumab 10 mg/kg | NA |
| Investigator-Choice Chemotherapy (ICC) | 6.8 |
OS was defined as the time from randomization to death due to any cause. Analysis of OS was not planned or conducted for the switch-to-pembrolizumab treatment groups. Median OS duration based on the product-limit (Kaplan-Meier) method for censored data is presented. This was the final analysis for OS. (NCT01704287)
Timeframe: Up to approximately 75 months (Through End of Trial Analysis database cutoff date of 31-Jan-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab 2 mg/kg | 13.4 |
| Pembrolizumab 10 mg/kg | 14.7 |
| Investigator-Choice Chemotherapy (ICC) | 11.0 |
OS was defined as the time from randomization to death due to any cause. Analysis of OS was not planned or conducted for the switch-to-pembrolizumab treatment groups. Median OS based on the product-limit (Kaplan-Meier) method for censored data is presented. This was the interim analysis for OS. (NCT01704287)
Timeframe: Up to approximately 36 months (Through Final Analysis database cutoff date of 16-Nov-2015)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab 2 mg/kg | 13.4 |
| Pembrolizumab 10 mg/kg | 14.7 |
| Investigator-Choice Chemotherapy (ICC) | 11.0 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition which is temporally associated with the use of study drug, was also an AE. The number of participants who discontinued study drug due to an AE is presented. (NCT01704287)
Timeframe: Up to approximately 75 months (Through End of Trial Analysis database cutoff date of 31-Jan-2019)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab 2 mg/kg | 29 |
| Pembrolizumab 10 mg/kg | 33 |
| ICC Only | 13 |
| ICC→Pembrolizumab 2 mg/kg | 1 |
| ICC→Pembrolizumab 10 mg/kg | 1 |
| ICC→Pembrolizumab 2 mg/kg (After Switch to Pembrolizumab) | 4 |
| ICC→Pembrolizumab 10 mg/kg (After Switch to Pembrolizumab) | 4 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of study drug, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition which was temporally associated with the use of study drug, was also an AE. Participants were included in the treatment group in which an AE was experienced. The number of participants who experienced at least one AE is presented. (NCT01704287)
Timeframe: Up to approximately 75 months (Through End of Trial Analysis database cutoff date of 31-Jan-2019)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab 2 mg/kg | 172 |
| Pembrolizumab 10 mg/kg | 179 |
| ICC Only | 71 |
| ICC→Pembrolizumab 2 mg/kg | 52 |
| ICC→Pembrolizumab 10 mg/kg | 45 |
| ICC→Pembrolizumab 2 mg/kg (After Switch to Pembrolizumab) | 53 |
| ICC→Pembrolizumab 10 mg/kg (After Switch to Pembrolizumab) | 41 |
ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. Analysis of ORR was not planned or conducted for the switch-to-pembrolizumab treatment groups. The percentage of participants who experienced a CR or PR is presented. This was the final analysis for ORR. (NCT01704287)
Timeframe: Up to approximately 36 months (Through Final Analysis database cutoff date of 16-Nov-2015)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab 2 mg/kg | 22.2 |
| Pembrolizumab 10 mg/kg | 27.6 |
| Investigator-Choice Chemotherapy (ICC) | 4.5 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Criteria in Solid Tumors version 1.1 (RECIST 1.1), PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm. Note: The appearance of one or more new lesions was also considered PD. Analysis of PFS was based on an integrated radiology and oncology (IRO) assessment and was not planned or conducted for the switch-to-pembrolizumab treatment groups. Median PFS based on the product limit (Kaplan-Meier) method for censored data is presented. This was the final analysis for PFS. (NCT01704287)
Timeframe: Up to approximately 36 months (Through Final Analysis database cutoff date of 16-Nov-2015)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab 2 mg/kg | 2.9 |
| Pembrolizumab 10 mg/kg | 3.0 |
| Investigator-Choice Chemotherapy (ICC) | 2.8 |
BOR was assessed by independent radiology review using RECIST 1.1 and was recorded from randomization until the last imaging assessment in this period. Response categories included: Complete Response (CR): disappearance of all target lesions; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD): at least a 20% increase in the sum of diameters of target lesions; and Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. BOR for the Initial Treatment Period was based on IRO. BOR for participants during the Initial Treatment Period is presented. (NCT01704287)
Timeframe: Up to approximately 36 months (Through Final Analysis database cutoff date of 16-Nov-2015)
| Intervention | Percentage of Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Not Evaluable | No Disease | No Assessment | |
| Investigator-Choice Chemotherapy (ICC) | 0.0 | 4.5 | 19.0 | 61.5 | 15.1 | 0.0 | 0.0 |
| Pembrolizumab 10 mg/kg | 7.2 | 20.4 | 14.9 | 47.5 | 9.9 | 0.0 | 0.0 |
| Pembrolizumab 2 mg/kg | 3.3 | 18.9 | 16.7 | 46.7 | 13.3 | 0.6 | 0.6 |
The BOR was assessed using RECIST 1.1 and was recorded from the start of the second line of study drug (pembrolizumab) until the last imaging assessment in this period. Response categories included: Complete Response (CR): disappearance of all target lesions; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD): at least a 20% increase in the sum of diameters of target lesions; and Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For the switch-to-pembrolizumab treatment groups, BOR was based on independent review committee (IRC) assessment. The BOR for switched-to pembrolizumab treatment groups is presented. (NCT01704287)
Timeframe: Up to approximately 36 months (Through Final Analysis database cutoff date of 16-Nov-2015)
| Intervention | Percentage of Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Not Evaluable | No Assessment | |
| ICC→Pembrolizumab 10 mg/kg | 4.4 | 13.3 | 11.1 | 55.6 | 13.3 | 2.2 |
| ICC→Pembrolizumab 2 mg/kg | 1.9 | 17.0 | 15.1 | 54.7 | 11.3 | 0.0 |
OS was defined as the time from randomization to death due to any cause. Participants with an Allred Proportion Score (APS) ≥2 (membranous staining in ≥1% of cells for PD-L1) were considered to be PD-L1 Positive and participants with an APS of 0 or 1 were considered to be PD-L1 Negative. Analysis of OS was not planned or conducted for the switch-to-pembrolizumab treatment groups. Median OS duration based on the product-limit (Kaplan-Meier) method for censored data by PD-L1 tumor expression status is presented. (NCT01704287)
Timeframe: Up to approximately 75 months (Through End of Trial Analysis database cutoff date of 31-Jan-2019)
| Intervention | Months (Median) | |
|---|---|---|
| PD-L1 Positive | PD-L1 Negative | |
| Investigator-Choice Chemotherapy (ICC) | 12.1 | 9.3 |
| Pembrolizumab 10 mg/kg | 17.5 | 13.4 |
| Pembrolizumab 2 mg/kg | 15.0 | 10.5 |
Duration of objective response was measured from the time the criteria were met for complete response or partial response to the first date that recurrent or progressive disease was objectively documented. (NCT00091572)
Timeframe: Treatment continued until disease progression or unacceptable toxicity.
| Intervention | Months (Median) |
|---|---|
| Temozolomide | 4.34 |
| Dacarbazine | 8.31 |
Based on investigator's assessment of response in subjects with measurable lesions. Objective response = complete response + partial response. Complete response = disappearance of all target lesions. Partial response = at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter. (NCT00091572)
Timeframe: Treatment continued until disease progression or unacceptable toxicity.
| Intervention | Ratio (Median) |
|---|---|
| Temozolomide | 0.14 |
| Dacarbazine | 0.10 |
Overall Survival was defined as the time from the date of randomization to the date of death from any cause. (NCT00091572)
Timeframe: The final analysis was to be performed when at least 616 deaths had occurred.
| Intervention | Months (Median) |
|---|---|
| Temozolomide | 9.13 |
| Dacarbazine | 9.36 |
Progression free survival was defined as the time from the date of randomization to the date of disease progression or the date of death regardless of the cause. (NCT00091572)
Timeframe: Treatment continued until disease progression or unacceptable toxicity. Patients will be followed for survival.
| Intervention | Months (Median) |
|---|---|
| Temozolomide | 2.30 |
| Dacarbazine | 2.17 |
Overall survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier. (NCT00626405)
Timeframe: Up to 5 years
| Intervention | Months (Median) |
|---|---|
| Arm I | 12.3 |
| Arm II | 13.9 |
The primary endpoint is the 6 month post registration Progression-free survival (PFS) rate. Progression-free survival time is defined as the time from registration to documentation of disease progression using the RECIST criteria. Patients who died without documentation of disease progression will be considered to have progressed at death unless there is sufficient documented evidence to conclude no progression occurred prior to death. All patients, who meet the eligibility criteria, sign a consent form, and start treatment will be included in the evaluation of the 6 month PFS rate. (NCT00626405)
Timeframe: at 6 months
| Intervention | % of patients alive and progression free (Number) |
|---|---|
| Arm I | 32.8 |
| Arm II | 56.1 |
"A confirmed tumor response is defined to be a Complete Response or Partial Response noted~> as the objective status on 2 consecutive evaluations at least 8~> weeks apart. The proportion of tumor responses will be~> estimated by the number of confirmed tumor responses divided~> by the total number of evaluable patients.~> Complete Response (CR): Disappearance of all target lesions~> Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.~> Progression (PD): At least a 20% increase in the sum of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.~> Stable Disease (SD): Neither sufficient shrinkage to Qualify for PR nor sufficient increase to Qualify for PD taking as reference the smallest sum LD. responses will be calculated assuming that the number of~> confirmed tumor responses follows a binomial distribution." (NCT00626405)
Timeframe: Up to 5 years
| Intervention | percentage of patients with response (Number) |
|---|---|
| Arm I | 23.8 |
| Arm II | 33.3 |
The primary endpoint of this trial is the 9 week PFS rate. A patient is a success if they are progression free at their cycle 2 evaluation (approximately 9 weeks post registration). All patients, who meet the eligibility criteria, sign a consent form, and start treatment will be included in the evaluation of the 9-week PFS rate (evaluable patients). The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated using the properties of the binomial distribution. If some patients are lost to follow up prior to their cycle 2 evaluation, the Kaplan-Meier method will be used to estimate the 9 week PFS rate. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00521001)
Timeframe: at 9 weeks
| Intervention | proportion of patients (Number) |
|---|---|
| Everolimus + Temozolomide | 0.44 |
Confirmed response rates will be evaluated by dividing the number of confirmed responders (i.e. patients that achieve a CR or PR on consecutive evaluations) by the total number of evaluable patients. Confidence intervals for the true response rate will be calculated using the properties of the binomial distribution. (NCT00521001)
Timeframe: Up to 5 years
| Intervention | percentage of confirmed responses (Number) |
|---|---|
| Everolimus + Temozolomide | 8.3 |
Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier. (NCT00521001)
Timeframe: Time from registration to death due to any cause; Up to 5 years
| Intervention | months (Median) |
|---|---|
| Everolimus + Temozolomide | 8.6 |
Time to disease progression is defined as the time from registration to the earliest date documentation of disease progression. If a patient dies without a documentation of disease progression the patient will be considered to have had tumor progression at the time of their death unless there is sufficient documented evidence to conclude no progression occurred prior to death. The distribution of time to progression will be estimated using the method of Kaplan-Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00521001)
Timeframe: Time from registration to the earliest date documentation of disease progression; Up to 5 years
| Intervention | months (Median) |
|---|---|
| Everolimus + Temozolomide | 2.4 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
16 reviews available for temozolomide and Skin Neoplasms
| Article | Year |
|---|---|
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2019 |
Plasmas for Treating Cancer: Opportunities for Adaptive and Self-Adaptive Approaches.
Topics: Animals; Antineoplastic Agents, Alkylating; Aquaporins; Cell Line, Tumor; Drug Resistance, Neoplasm; | 2018 |
Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.
Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; D | 2013 |
What is the role of chemotherapy in the treatment of melanoma?
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carboplatin; Cisplatin; Clinical Trials as Topic; Dac | 2014 |
Current systemic therapies for melanoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Bridged-Ring Compounds; Dacarbazine; Humans; | 2014 |
Temozolomide for Treating Malignant Melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Melanoma, Cutaneo | 2015 |
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; Dermatologic Sur | 2016 |
Multiple intracranial melanoma metastases: case report and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; | 2009 |
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2011 |
[Therapeutic strategies and systemic treatment of brain melanoma metastases].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modali | 2013 |
[Treatment of melanoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2003 |
[Therapy of malignant melanoma at the stage of distant metastasis].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2004 |
The role of taxanes in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Da | 2004 |
Management of metastatic cutaneous melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clini | 2004 |
Systemic treatments for advanced cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Com | 1995 |
Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Biological Availability; Brain Neoplasms; D | 2000 |
53 trials available for temozolomide and Skin Neoplasms
| Article | Year |
|---|---|
Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Melanoma; Pyridines; Skin Neo | 2022 |
A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Dacarbazine; Female; Humans; Ipilimumab; Male; Me | 2017 |
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease | 2013 |
Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dacarbazine; Dose- | 2014 |
Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Daca | 2014 |
A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Dacarbazine; DNA Methyla | 2015 |
A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2016 |
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2016 |
Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; CD11c Antigen; CD3 Co | 2017 |
A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedu | 2008 |
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cohort Stud | 2009 |
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Child; Dacarbazine; Dose-Response Relationsh | 2009 |
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; | 2010 |
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemokines; | 2010 |
Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazi | 2010 |
Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dacarbazin | 2011 |
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intrav | 2011 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intrav | 2011 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intrav | 2011 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intrav | 2011 |
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; D | 2011 |
A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2013 |
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Apo | 2013 |
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dac | 2013 |
Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease | 2014 |
Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease | 2003 |
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 2003 |
A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ca | 2003 |
Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cognition; | 2003 |
Temozolomide as prophylaxis for melanoma brain metastases.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine | 2004 |
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dis | 2004 |
Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedu | 2004 |
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2005 |
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2005 |
Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2006 |
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma.
Topics: Aged; Dacarbazine; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms; T | 2005 |
Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarb | 2005 |
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; DNA Methylation; DNA, Neopla | 2005 |
A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine | 2006 |
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Eye Neo | 2006 |
A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Dose- | 2006 |
Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fema | 2006 |
Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Immunologi | 2006 |
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhi | 2006 |
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2006 |
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2006 |
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Daca | 2008 |
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.
Topics: Adult; Aged; Antineoplastic Agents; Cancer Vaccines; Dacarbazine; Female; Heat-Shock Proteins; Human | 2008 |
Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; I | 2008 |
Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap | 2008 |
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain | 1999 |
Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dacarbazine; | 2000 |
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2002 |
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality T | 2002 |
80 other studies available for temozolomide and Skin Neoplasms
| Article | Year |
|---|---|
Identification and validation of TME-related signatures to predict prognosis and response to anti-tumor therapies in skin cutaneous melanoma.
Topics: Carrier Proteins; Cisplatin; Humans; Melanoma; Melanoma, Cutaneous Malignant; Skin Neoplasms; Temozo | 2023 |
Core‑shell type thermo‑nanoparticles loaded with temozolomide combined with photothermal therapy in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Combined Modality Therapy; Drug Carriers; Drug | 2019 |
Discovering pH triggered charge rebound surface modulated topical nanotherapy against aggressive skin papilloma.
Topics: Animals; Apoptosis; Biocompatible Materials; Cell Line; Chitosan; Down-Regulation; Drug Carriers; Dr | 2020 |
Chemotherapy Following PD-1 Inhibitor Blockade in Patients with Unresectable Stage III/Stage IV Metastatic Melanoma: A Single Academic Institution Experience.
Topics: Academic Medical Centers; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Imm | 2020 |
Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Female; Follow-Up Studies; H | 2021 |
Spindle cell melanoma coexisting with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare collision tumor in multiple sites.
Topics: Aged, 80 and over; Antigens, CD20; Antineoplastic Agents, Alkylating; Biopsy; CD5 Antigens; Fatal Ou | 2020 |
Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell L | 2017 |
The real-world impact of modern treatments on the survival of patients with metastatic melanoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, I | 2019 |
Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Female; Humans; Male; Me | 2019 |
Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2014 |
Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Drug Adminis | 2014 |
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Combined Modality Th | 2014 |
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Stud | 2014 |
Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Community Health Services; Dacarbazi | 2014 |
Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cadherins; Capillary Permeabil | 2015 |
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.
Topics: Adult; Aged; Antineoplastic Agents; Cystatin B; Dacarbazine; Drug Resistance, Neoplasm; Factor XIII; | 2014 |
Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA; DNA Methylation; Enzy | 2014 |
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Daca | 2015 |
Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Colitis; Dacarbazine; Fluorodeoxyglucose | 2014 |
Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; | 2015 |
c-Myc modulation: a key role in melanoma drug response.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dacarbazine; Doxorubicin; Drug Resistance, N | 2015 |
Comparative healthcare costs in patients with metastatic melanoma in the USA.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Female; Health Care Costs; Humans; Immun | 2015 |
Temozolomide for central nervous system involvement in mycosis fungoides.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Dacarbazine; | 2016 |
DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines.
Topics: Acetylation; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Chromatin Immunoprecipitati | 2016 |
Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells.
Topics: Alkylating Agents; Apoptosis; Bortezomib; Cell Cycle Checkpoints; Cell Division; Cyclin-Dependent Ki | 2016 |
Evaluating the cytotoxic effects of the water extracts of four anticancer herbs against human malignant melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2016 |
Autophagy inhibitors chloroquine and LY294002 enhance temozolomide cytotoxicity on cutaneous melanoma cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Cell Prolife | 2017 |
Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dacarbazine; Databases, Factual; Female; Humans; Ind | 2017 |
Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Dacarbazine; Dose-Response Relation | 2008 |
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Dacarbazine; Drug Delivery Sys | 2009 |
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazi | 2009 |
Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine.
Topics: Aged; Antineoplastic Agents, Alkylating; Azathioprine; Carcinoma, Basal Cell; Carcinoma, Squamous Ce | 2009 |
The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Docetaxel; Humans; | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neo | 2010 |
Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Male | 2010 |
Enhancing melanoma treatment with resveratrol.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Di | 2012 |
Positron emission tomography/computed tomography: use for initial staging of malignant melanoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Axilla; Dacarbazine; Fatal Outcome; Humans; Liver Neoplasms | 2010 |
Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Dose-Response Rela | 2010 |
siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; G1 | 2011 |
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Count; C | 2011 |
NRAS-mutant melanoma: response to chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Genes, ras; Humans; | 2011 |
Melanoma-associated retinopathy: a presenting sign of metastatic disease.
Topics: Antineoplastic Agents, Alkylating; Biopsy, Fine-Needle; Dacarbazine; Follow-Up Studies; Humans; Immu | 2011 |
[News on melanoma from the 2010 Dermatology Days in Paris].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Chemotherapy, | 2011 |
[Cutaneous neutrophils infiltrates. Case 4. Pseudo-tumoral cutaneous alternariosis].
Topics: Aged, 80 and over; Alternaria; Antifungal Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms | 2011 |
Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.
Topics: Animals; Cell Movement; Chemokine CCL5; Chemokine CXCL9; Chemokines; Dacarbazine; Humans; Melanoma; | 2011 |
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.
Topics: Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Dacarbazine; Exome; Humans; Loss of Heterozy | 2011 |
Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bec | 2012 |
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette | 2012 |
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aldehyde Oxidoreductases; Animals; Apoptosi | 2012 |
Cancer: Resolving the stem-cell debate.
Topics: Animals; Brain Neoplasms; Cell Lineage; Cell Tracking; Dacarbazine; Female; Glioblastoma; Humans; Ma | 2012 |
Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calcium Channel Blockers; Cell Cycle; D | 2013 |
[Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neopl | 2002 |
[Complete response of cerebral metastasic melanoma after a combined treatment of radiotherapy and temozolomide].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; | 2002 |
Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Drug Therapy, Co | 2003 |
DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system.
Topics: Antineoplastic Agents, Alkylating; Burkitt Lymphoma; Cell Division; Dacarbazine; DNA Damage; DNA Rep | 2003 |
Quality of life, at what cost?
Topics: Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Humans; Melanoma; | 2003 |
Metastatic malignant melanoma presenting as a cavernous sinus syndrome.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Blepharoptosis; Cavernous Sinus Thrombosis; Cranial | 2004 |
Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dermatitis, Phototoxic; Female; Humans; | 2004 |
Complete response of multiple melanoma brain metastases after treatment with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Magnetic Resonance | 2004 |
Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Per | 2004 |
Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazi | 2004 |
Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Di | 2005 |
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Pro | 2005 |
Skin delivery potency and antitumor activities of temozolomide ester prodrugs.
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents, Alkylating; Cell Membrane Permeability; C | 2006 |
Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Mo | 2006 |
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2006 |
[Phototoxicity of dacarbazine (Deticene) not reinduced by temozolomide (Temodal)].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Dermatitis, Phototoxic; Humans; Melanoma; Skin Neopl | 2006 |
Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Cancer Vaccines; Cell Line, Tumor; Cell Proli | 2007 |
Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Base Pair Mismatch; Cell Line, Tumor; Dacarbazine; Female; Gene Expr | 2007 |
Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cathepsin B; Cell Line | 2007 |
Microemulsions as topical delivery vehicles for the anti-melanoma prodrug, temozolomide hexyl ester (TMZA-HE).
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Detergents; Drug | 2007 |
Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Chemotherapy, Adjuvan | 2007 |
O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Blotting, Western; Dac | 2007 |
Acquired hypopigmentation (leukoderma) as a presenting feature of metastatic amelanotic melanoma with brain involvement.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; De | 2007 |
Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Eruptions; Female; Humans; Melanoma; Ski | 2008 |
A rare case of melanoma recurring as subcutaneous metastatic melanoma with overlying ecchymoses.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Ecchymosis; Female; Human | 2008 |
Temozolomide for advanced, metastatic melanoma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma; Proportional Hazards Models; Quali | 2000 |
What's new in the treatment of melanoma?
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Hu | 2000 |
Treatment of brain metastases of malignant melanoma with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Magnetic Re | 2001 |